Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 1 of 65 
 Clinical Trial Protocol : THR-1442 -C-449 
 
Study Title:  A Phase 2b, Multi -center, Double -blind, Placebo -controlled, Dose 
Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on 
HbA1c in Subjects with Type 2 Diabetes Mellitus  
Study Number:  THR -1442 -C-449 
Study Phase:  2b 
Product Name:  Bexagliflozin tablets  
Indication:  Type 2 Diabetes Mellitus  
Investigators:  Multi -center study  
  
Sponsor:  Theracos, Inc. 
Sponsor Contact:  Albert Collinson, Ph.D.  
Theracos, Inc.  
225 Cedar Hill Street, Suite 200, Marlborough, MA 01752  
Phone: 508 -688-4221  
 
Medical Monitor:  Geoffrey Walford, M.D.  
Massachusetts General Hospital  
185 Cambridge Street, Boston, MA 02114  
Phone:   617-643-4986  
Fax:  617 -643-3328  
E-mail:  gwalford@partners.org  
 
 
 Date  
Original  Protocol : 29 September 2014  
Protocol Revision  16 February 2015  
 
Confidentiality Statement  
The information contained in this protocol is confidential and provided only to the 
investigators, clinical study collaborators, investigational drug managers, study sites and 
institutional review boards participating in the study. The information may, therefore, not be, 
disclosed to any t hird party except for subjects when receiving their consent, or used for 
purposes other than this study without the written consent of Theracos, Inc.   
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 2 of 65 
 TABLE OF CONTENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ .6 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .......... 10 
1 INTRODUCTION  ................................ ................................ ................................ ........... 12 
1.1 Bexagliflozin for the Treatment of Type 2 Diabetes Mellitus  ............................... 13 
1.1.1  Summary of Non -clinical Data with Bexagliflozin  ................................ .....13 
1.1.2  Summary of Clinical Data with Bexagliflozin ................................ ............. 13 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....14 
2.1 Primary Objective  ................................ ................................ ................................ ..14 
2.2 Secondary Objectives ................................ ................................ ............................. 14 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 15 
3.1 Overall Study Design and Plan  ................................ ................................ .............. 15 
3.2 Research Methods and Procedures  ................................ ................................ ........ 15 
3.2.1  Washout and Run -in Period  ................................ ................................ ......... 15 
3.2.2  Treatment Period  ................................ ................................ .......................... 17 
3.2.3  Glycemic Control Monitoring ................................ ................................ ......17 
3.3 Rationale for Study Design and Control Group  ................................ ..................... 20 
3.4 Study Duration and Dates  ................................ ................................ ...................... 21 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ........... 22 
4.1 Study Population  ................................ ................................ ................................ ....22 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...22 
4.3 Exclusion Criteria  ................................ ................................ ................................ ..22 
5 STUDY TREATMENTS  ................................ ................................ ................................ .24 
5.1 Description of Treatments ................................ ................................ ...................... 24 
5.1.1  Investigational Product  ................................ ................................ ................ 24 
5.2 Treatments Administered  ................................ ................................ ....................... 24 
5.3 Selection and Timing of Dose for Each Patient  ................................ ..................... 24 
5.4 Method of Assigning Patients to Treatment Groups ................................ .............. 24 
5.5 Blinding ................................ ................................ ................................ .................. 25 
5.6 Concomitant Therapy ................................ ................................ ............................. 25 
5.7 Restrictions  ................................ ................................ ................................ ............ 26 
5.7.1  Prior Therapy  ................................ ................................ ............................... 26 
5.7.2  Fluid and Food Intake  ................................ ................................ .................. 26 
5.7.3  Patient Activity Restrictions  ................................ ................................ ........ 26 
5.8 Treatment Compliance  ................................ ................................ ........................... 27 
5.9 Packaging and Labeling  ................................ ................................ ......................... 27 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 3 of 65 
 5.9.1  Run-in Kit  ................................ ................................ ................................ ....27 
5.9.2  Investigational Product Kit  ................................ ................................ .......... 27 
5.10  Storage and Accountability  ................................ ................................ .................... 27 
5.11  Investigational Product Retention at Study Site  ................................ .................... 27 
6 STUDY PROCEDURES  ................................ ................................ ................................ .29 
6.1 Informed Consent ................................ ................................ ................................ ...29 
6.2 Medical History  ................................ ................................ ................................ .....29 
6.2.1  General Demographics and Characteristics  ................................ ................. 29 
6.2.2  Diabetes History ................................ ................................ ........................... 29 
6.2.3  Cardiovascular Disease History  ................................ ................................ ...29 
6.2.4  Medication History  ................................ ................................ ...................... 29 
6.3 Physical Examination ................................ ................................ ............................. 30 
6.4 Vital Signs  ................................ ................................ ................................ .............. 30 
6.4.1  Blood Pressure and Pulse Measurements  ................................ .................... 30 
6.4.2  Temperature and Respiratory Rate  ................................ .............................. 31 
6.5 Electrocardiography  ................................ ................................ ............................... 31 
6.6 Diet and Exercise Counseling  ................................ ................................ ................ 31 
6.7 Clinical Laboratory Tests  ................................ ................................ ....................... 31 
6.7.1  Laboratory Parameters  ................................ ................................ ................. 31 
6.7.2  Sample Collection, Storage, and Shipping  ................................ .................. 33 
6.7.2.1  Hematology, Blood Chemistry, Serum Lipids, and Glycemic 
Control Assessments  ................................ ................................ .......... 33 
6.7.3  Urinalysis  ................................ ................................ ................................ .....33 
6.7.4  Population PK Sampling  ................................ ................................ .............. 34 
6.8 Dispensing Investigational product ................................ ................................ ........ 34 
6.9 Efficacy Assessments ................................ ................................ ............................. 34 
6.9.1  HbA1c Determination  ................................ ................................ .................. 34 
6.9.2  Body Weight  ................................ ................................ ................................ 35 
6.9.3  Bloo d Pressure  ................................ ................................ ............................. 35 
6.10  Adverse Events Assessments  ................................ ................................ ................. 35 
6.10.1  Eliciting and Reporting Adverse Events  ................................ ...................... 36 
6.10.2  Immediately Reportable Adverse Events  ................................ ..................... 37 
6.10.3  Pregnancy  ................................ ................................ ................................ .....37 
6.10.4  Procedure for Breaking the Blind  ................................ ................................ 38 
6.10.5  Follow -up of Adverse Events  ................................ ................................ ......38 
6.10.5.1  Follow -up of Non -serious Adverse Events  ................................ ........ 38 
6.10.5.2  Follow -up of Post -Study Serious Adverse Events  ............................. 39 
6.10.6  Urinary Tract Infections (UTIs)  ................................ ................................ ...39 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 4 of 65 
 6.10.7  Genital Mycotic Infections (GMIs)  ................................ ............................. 39 
6.10.8  Hepatotoxicity  ................................ ................................ .............................. 40 
6.10.9  Hypoglycemia  ................................ ................................ .............................. 40 
6.11  Concomitant Medication Assessments  ................................ ................................ ..42 
6.12  Removal of Patients from the Trial or Discontinuation of Investigational 
Product Administration  ................................ ................................ .......................... 43 
6.13  Appropria teness of Measurements  ................................ ................................ ......... 43 
7 STUDY ACTIVITIES  ................................ ................................ ................................ .....44 
7.1 Screening (Up to 15 weeks prior to randomization, visit S1)  ................................ 44 
7.2 Washout and Run -in Periods (Up to 12 weeks prior to randomization)  ................ 44 
7.2.1  Washout of OHA (Visits S2 and S3)  ................................ ........................... 44 
7.2.1.1  Visit S2 (subjects taking one OHA) ................................ ................... 45 
7.2.1.2  Visit S3 – Phone interview (subjects in washout)  ............................. 45 
7.2.2  Run-in Period:  ................................ ................................ .............................. 45 
7.2.2.1  Visit S4 (Week -2) ................................ ................................ ............. 45 
7.2.2.2  Visit S5 (Days -3 to -5) ................................ ................................ ......46 
7.3 Treatment Period (week 1 to week 12)  ................................ ................................ ..46 
7.3.1  Visit V1 (Day 1 of week 1)  ................................ ................................ .......... 46 
7.3.2  Visit V2 (week 2)  ................................ ................................ ......................... 46 
7.3.3  Visit V3 (week 6)  ................................ ................................ ......................... 47 
7.3.4  Visit V4 (week 12)  ................................ ................................ ....................... 47 
7.4 Exit Visit or Early Termination Visit  ................................ ................................ .....48 
7.4.1  Visit V5 (week 14 or two weeks after the last dose of investigational 
product if a subject early terminates)  ................................ ........................... 48 
7.5 Early Termination Procedures  ................................ ................................ ............... 48 
8 QUALITY CONTROL AND ASSURANCE  ................................ ................................ .48 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 49 
9.1 General Considerations  ................................ ................................ .......................... 49 
9.1.1  Handling Dropouts, and Missing Data ................................ ......................... 49 
9.1.2  Multiple Comparisons / Multiplicity  ................................ ........................... 50 
9.2 Determination of Sample Size  ................................ ................................ ............... 50 
9.3 Analysis Populations  ................................ ................................ .............................. 50 
9.3.1  Full Analysis Set  ................................ ................................ .......................... 50 
9.3.2 Safety Analysis Set  ................................ ................................ ...................... 50 
9.3.3  Per Protocol Analysis Set ................................ ................................ ............. 51 
9.4 Demographics and Baseline Characteristics  ................................ .......................... 51 
9.5 Analysis of Efficacy  ................................ ................................ ............................... 51 
9.6 Analysis of Safety  ................................ ................................ ................................ ..52 
9.6.1  Adverse Events  ................................ ................................ ............................ 52 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 5 of 65 
 9.6.2  Adverse Events of Special Interest  ................................ .............................. 53 
9.6.3  Clinical and Laboratory Events and Analyses  ................................ ............. 53 
9.6.4  Physical Examination ................................ ................................ ................... 54 
9.6.5  Concomitant Medications  ................................ ................................ ............ 54 
9.7 Interim Analysis  ................................ ................................ ................................ .....54 
10 ADMINISTRATIVE CONSI DERATIONS  ................................ ................................ ....55 
10.1  Investigators and Study Administrative Structure  ................................ ................. 55 
10.2  Institutional Review Board or Independent Ethics Committee Approval  ............. 55 
10.3  Ethical Conduct of the Study  ................................ ................................ ................. 55 
10.4  Subject Information and Consent ................................ ................................ ........... 56 
10.5  Subject Confidentiality  ................................ ................................ .......................... 56 
10.6  Study Monitoring  ................................ ................................ ................................ ...56 
10.7  Case Report Forms and Study Records  ................................ ................................ .57 
10.8  Data and Safety Monitoring Board  ................................ ................................ ........ 57 
10.9  Protocol Violations/Deviations  ................................ ................................ .............. 57 
10.10  Access to Source Documentation  ................................ ................................ .......... 57 
10.11  Retention of Data  ................................ ................................ ................................ ...58 
10.12  Publication and Disclosure Policy  ................................ ................................ ......... 58 
11 REFERENCE LIST  ................................ ................................ ................................ ......... 59 
 
LIST OF IN -TEXT TABLES  
Table  1. List of Laboratory Tests  ................................ ................................ ............... 32 
 
LIST OF IN -TEXT FIGURES  
Figure  1. Glycemic Control Requirement s Prior to Randomization  ........................... 16 
Figure  2. Dose related glucosuria in healthy Japanese subjects  ................................ ..21 
Figure  3. THR -1442 -C-449 Study Design  ................................ ................................ ..21 
 
LIST OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ............. 60 
Appendix 2  Schedule of Laboratory Tests  ................................ ............................ 62 
Appendix 3  Estimating Glomerular Filtration Rate ................................ ............... 63 
Appendix 4  Sponsor Signatures ................................ ................................ ............. 64 
Appendix 5  Investigator’s Signature  ................................ ................................ .....65 
 
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 6 of 65 
 SYNOPSIS  
Sponsor : 
Theracos, Inc. 
Name of Finished Product:  
Bexagliflozin tablets   
Name of Active Ingredient:  
(2S,3R,4R,5S,6R) -2-(4-chloro -3-(4-(2-cyclopropoxyethoxy) -benzyl)phenyl) -6-
(hydroxymethyl) -tetrahydro -2H-pyran -3,4,5 -triol 
Code name: EGT0001442  
 
Study  Title : 
A Phase 2b, Multi -center, Double -blind, Placebo -controlled, Dose Range Finding Study to 
Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects with Type 2 Diabetes 
Mellitus   
Study Number:  
THR -1442 -C-449 
Study Phase:  2b 
Primary Objective:   
The primary objective of this study is to identi fy dose (s) for further clinical study  through the 
comparison of HbA1c change from baseline in each active group that will receive 
bexagliflozin tablets, 5 mg, 10 mg, or 20 mg , to the placebo group over 12 weeks of 
treatment.  
Secondary Objective s: 
• To assess the change in HbA1c over time  
• To assess the efficacy of bexagliflozin tablets in lowering FPG as a function of time  
• To assess the efficacy of bexagliflozin based on the proportion of subjects who reach the 
American Diabetes Association (ADA) and the Japan Diabetes Society target  HbA1c of 
<7%  
• To assess the effect of bexagliflozin on systolic and diastolic blood pressure over time  
• To assess the effect of bexagliflozin on body weight over time  
• To assess the safety of bexagliflozin in subjects with T2 DM 
 
Other endpoint:  
Population pharmacokinetic evaluation of bexagliflozin plasma concentration  
 
Study Design : 
THR -1442 -C-449 is a phase 2b multicenter, double -blind, placebo -controlled parallel group 
study to assess the effect  of once daily bexagliflozin  tablets on HbA1c in either treatment -
naïve type 2 diabetic subjects or in subjects who have been treated with one oral anti -diabetic 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 7 of 65 
 agent.  To be eligible, a prospective subject of either gender must have  T2DM and an HbA1c 
value  between 7% and 8 .5% at the screening visit if treatment naïve or an HbA1c value 
between 6.5% and 8 .5% if currently treated with  one oral hypoglycemic agent and willing to 
undergo  a 6 or 10 week washout.   
All eligible subjects who are treatment naïve  or who have completed the wa shout will start a 
2 week placebo run -in period.  Subjects who are deemed complian t in taking the run-in 
medication ( i.e., miss no more than one dose  during the run -in period ) and have HbA1c 
between 7 and 8 .5% at the end of the run -in period will be eligib le for randomization and will 
receive investigational product . 
Approximately 320 subjects divided equally into  4 group s will be randomly assigned to take 
oral bexagliflozin  tablets , 5 mg, 10 mg, 20 mg , or placebo , once daily for 12 weeks in an out -
patient setting.  Subjects with hyperglycemia based on fasting blood glucose levels may 
receive approved anti -diabetic medication . 
Subjects will visit their study sites  at weeks 2, 6, and 12  for safety and efficacy evaluation , 
with a  follow -up visit at week 14. 
Measurement  of bexagliflozin  plasma concentration over time  (sparsely sampled) will also 
be conducted at 20 centers  and will  include approximately 240 study subjects as part of a 
bexag liflozin population PK study.  
 
Study Population :  
Approximately 320 diabetic subjects will be randomized.   
Prospective subjects must be : 
1. Men or women ≥ 20 years of age  at screening . Women of childbearing potential must test 
negative by urine pregnancy test and agree to abstain from coitus  or use contraception 
during the entire study period to avoid any possible pregnancy.  Females who are 
surgically sterile ( by reason of hysterectomy  or oophorectomy) or postmenopausal ( most 
recent mense s more  than 12 months  prior to screening ) are eligible if they test negative 
by urine pregnancy test.  
2. Treatment naïve ( i.e., have never received prescription anti-diabetic medications or have 
received no more than 14 days of prescription  medications fo r diabetes in the 12 weeks 
prior to enrollment ) or currently taking  one OHA in combination with diet and exercise  
3. Diagnosed with T2DM with HbA1c levels at screening between 7.0% and 8 .5% 
(inclusive) if treatment naïve  or with HbA1c levels between 6.5 an d 8.5% (inclusive) if 
on one oral anti -diabetic medication  
4. Currently having a body mass index (BMI) ≤ 40 kg/m2 
5. Taking stable doses of medication for hypertension or hyperlipidemia as determined by 
adherence to a regimen that has not changed for at least 30 days prior to screening  (if 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 8 of 65 
 applicable ) 
6. Able to comprehend the study participation requirements and willing to provide written 
informed consent in accordance with institutional and regulatory guidelines  
7. Able to  maintain adequate glycemic con trol at the run -in visit ( for subjects who complete 
the washout ) 
8. Having  an HbA1c between 7.0 and 8.5% (inclusive) p rior to randomization (day -3 to -5):  
9. Capable of adhering to the  investigational product  administration requirements as 
evidenced by omission of  no more than one dose of run -in medication  
 
Test Product, Dose , and Mode of Administration:   
Bexagliflozin  tablets, 5, 10, 20 mg  or placebo , once daily by mouth  before breakfast  
Duration of Treatment:   
12 weeks  
Efficacy  Assessments : 
Primary efficacy assessment:  
• Change in HbA1c  over 12 weeks of treatment  
 
Secondary efficacy assessments:  
• Change in HbA1c over time   
• Proportion of subjects with HbA1c <7%  
• Change in body weight over time  
• Change in FPG  over time  
• Change in systolic and diastolic bloo d pressure  over time  
 
Samples for population PK analysis will be collected and the required plasma concentration s 
determined.  The PK parameters  will be assessed separately as part of the population PK 
analysis.  
 
Safety  Assessments :  
Safety will be assessed based  on an analysis of the a dverse events record ; of laboratory data , 
including hematology, serum chemistry, urinalysis, urinary electrolytes and creatinine ; of 
electrocardiogram s (ECG s), vital signs  and physical examinations ; and of concomitant 
medication use.  
Statistical Methods:   
Data summaries will use descriptive statistics (number of subjects [n], mean, standard 
deviation [SD], Q1, median, Q3, minimum, and maximum) for continuous variables, and 
frequency and percentage for ca tegorical and ordinal variables.  If there are missing values, 
the number missing will be presented, but without a percentage.   All data collected will be 
included in by -subject data listings.  
For the primary endpoint  of HbA1c  change from baseline over 12 weeks of treatment , a 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 9 of 65 
 mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA) with 
baseline HbA1c as a covariate will be fitted  on the available data, incorporating all visits at 
which HbA1c was measured  from each subject including  the scheduled visits at weeks 2, 6, 
and 12 as well as the unscheduled visits for measurement of HbA1c . Treatment , study center,  
and stratification factor for randomization (treatment naïve versus  taking one OHA  at 
baseline)  will be applied as fixed effects, as will study week  and study week -by-treatment 
interaction. From this model, an estimate of the treatment difference at week 12 will be 
generated, as will an assessment of whether this estimate is significantly different when 
comparing placebo with each dose of  bexagliflozin  at a two -sided 0.05 level of significance. 
An unstructured within -patient covaria nce structure will be assumed. HbA1c values obtained 
after the start of rescue medication will be excluded from this primary analysis.   
The MMRM model is one appro ach to obtain treatment effect estimates in the presence of 
missing data. As sensitivity analyses for missing data, the following will be performed:  
1. Missing HbA1c data (for weeks 2, 6, or 12) will be imputed via multiple imputation , 
following which the MMR M will be repeated on the complete datasets with results 
combined across complete datasets using standard MI techniques; HbA1c values 
collected after the start of rescue medication will be considered missing.  
2. Missing HbA1c data will be imputed via LOCF, fo llowing which the MMRM will be 
repeated; HbA1c values collected after the start of rescue medication will be considered 
missing.  
3. HbA1c values collected after the start of rescue medication will NOT be considered 
missing , and the MMRM analyses will be re -performed.  
 
The effect of bexagliflozin on fasting blood glucose, blood pressure, body weight, change in 
HbA1c over time , and proportion of subjects who reach HbA1c <  7% will be evaluated as 
secondary endpoints. These endpoints are considered exploratory and will not be adjusted for 
multiplicity.  
Safety and tolerability of bexagliflozin in subjects with T2DM will also be assessed  
descriptively.  Data summaries will be produced for AEs, physical exam results, vital signs, 
ECG results, and clinical lab results including serum chemistry, hematology, serum lipids, 
glycemic control parameters and urinalysis.  
Date of Original Approved Protocol : 29 September 2014  
Date of Revised Protocol: 16 February 2015  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 10 of 65 
 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
ADA  American Diabetic Association  
AE Adverse event  
ALT  Alanine aminotransferase  
ALP  Alkaline phosphatase  
ANCOVA  Analysis of covariance  
ANOVA  Analysis of variance  
AST  Aspartate aminotransferase  
ATC  Anatomic therapeutic chemical  
BMI  Body mass index  
BUN  Blood urea nitrogen  
CI Confidence interval  
CK Creatinine kinase  
CRF  Case report form  
CRO  Contract research organization  
CV Cardiovascular  
DPP4  Dipeptidyl peptidase 4  
DSMB  Data and Safety Monitoring Board 
ECG  Electrocardiogram  
eGFR  Estimated glomerular filtration rate  
FAS Full analysis set  
FPG Fasting plasma glucose  
-GTP  Gamma -glutamyl transferase  
GCP  Good Clinical Practice  
GLP -1 Glucagon -like peptide -1 
h Hour  
HbA1c  Glycated hemoglobin  
HBsAg  Hepatitis B surface antigen  
Hct Hematocrit  
HCV  Hepatitis C virus  
HDPE  High density polyethylene  
HF Heart failure  
Hgb Hemoglobin  
HIPAA  Health Information Portability and Accountability Act  
HIV Human immunodeficiency virus  
ICCR  In country caretaker representative  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 11 of 65 
 IRAE  Immediately reportable adverse event  
IRB Institutional Review Board  
ITT Intent -to-treat 
IWRS  Interactive web response system  
LDH  Lactic dehydrogenase  
MACE  Major adverse cardiovascular event  
MDRD  Modification of diet in  renal disease  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocardial infarction  
MMRM  Mixed model repeated measures  
MODY  Maturity –Onset Diabetes of the Young  
NYHA  New York Heart Association  
OHA  Oral hypoglycemi c agent  
PD Pharm acodynamics  
PK Pharm acokinetics  
SAE  Serious adverse event  
SBP Systolic blood pressure  
SD Standard deviation  
SGLT2  Sodium glucose cotransporter 2  
SMBG  Self-monitored blood glucose  
SOP Standard operating procedure  
T2DM  Type 2 diabetes mellitus  
TEAE  Treatment emergent adverse event  
TIA Transient ischemic attack  
UACR  Urine a lbumin -to-creatinine  ratio 
UGE  Urinary glucose excretion  
ULN  Upper limit of normal  
UPT  Urine pregnancy test  
UTI Urinary tract infection  
WOCBP  Woman of child  bearing potential  
WHO -DD World Health Organization Drug Dictionary  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 12 of 65 
 1 INTRODUCTION  
Type 2 diabetes mellitus (T2DM) is one of the leading causes of morbidity and mortality 
worldwide, affecting an estimated 38 7 million people in 201 4 and reaching  epidemic 
proportions in nearly all co untries in the world .  Approximately 1 79 million of those affected 
are estimated to be  unaware of their condition and over 80% reside in low - and middle -
income countries (International Diabetes Foundation, 2014).  T2DM accounts for at least 
90% of all diab etes cases . Despite the availability of several classes of therapeutics, the 
number of people with T2DM  is projected to increase by 55% to over 590 million adults by 
2035.  Among the debilitating consequences of T2DM are peripheral neuropathy, 
retinopathy,  renal failure, peripheral ischemia and exacerbations of cardiovascular disease, 
which result in blindness, amputation, dialysis and death.  
T2DM is a disease of insulin resistance  and is strongly linked to increased body fat mass  in 
the majority of cases (Schwartz et al., 2012 ).  Weight loss has been shown to improve 
glycemic control and to reduce the severity of diabetes -associated comorbidit ies, supporting 
the view that anti -diabetic agents that promote weight loss may be particularly beneficial for 
the treatment of the disease  (Look et al., 2013 ; Scheen and Van Gaal, 2014 ).   
Asian populations may be par ticularly at risk for the adverse consequences of increased body 
mass. Metabolic syndrome, a presentation  of diabetes with comorbid hypertension and 
dyslipidemia, increases more rapidly with increasing weight among Asians than among non -
Asians and it has b een proposed that the BMI ranges that define the overweight and obese 
categories should be lower in Asian populations than in non -Asian populations (Palaniappan 
et al., 2011 ).  
Several classes of agents are available for treating T2DM, including insulin and its 
secretagogues, PPAR  agonists, biguanides, alpha glucosidase inhibitors, glucagon -like 
peptide 1 (GLP -1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors.  However, 
the rapid growth rate in the incidence of T2DM has led to an increasing recognition that 
addition al therapeutics are needed to provide safe and effective reductions of elevated plasma 
glucose levels.  New agents to treat T2DM will ideally reduce  hyperglycemia and avoid 
common side effects of currently available agents, such as weight gain, gastrointes tinal 
disturbance s, and hypoglycemia.  
The renal Na+/glucose transport protein SGLT2 actively transports extracellular glucose into 
cells using the driving energy of the transmembrane electrochemical potential for sodium 
ions.  Individuals with disruptions in SLC5A2, the gene encoding SGLT2, exhibit prominent 
glucosuria in the absence of significant co -morbidities (Santer et al., 2003 ; van den Heuvel et 
al., 2002 ).  The excretion of glucose in the urine  of diabetic subjects in amounts comparable 
to or greater than that seen in individuals harboring loss of functions mutations in SLC5A2 
has the potential to improve both fasting and postprandial hyperglycemia without increasing 
insulin secretion, causing w eight gain, or inducing hypoglycemia.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 13 of 65 
 1.1 Bexagliflozin  for the Treatment of Type 2 Diabetes Mellitus  
Bexagliflozin  (previously identified as  EGT0001442) , is a potent and  highly specific 
inhibitor of the SGLT2 with an in vitro  IC50 of 2 nM  or 0.9 ng/mL and a 2435 -fold selectivity 
for human SGLT2 compared with SGLT1.  Bexagliflozin  elicits a prominent and predictable 
glucosuria in laboratory animals and human subjects .   
1.1.1  Summary of Non-clinical Data with Bexagliflozin  
The potential adverse e ffects of bexagliflozin  have been evaluated in studies of  non-clinical 
safety pharmacology, acute and chronic general toxicology, genotoxicity, acute and chronic 
reproductive toxicity and two -year carcinogenicity.  Repeat dose toxicity studies have found 
exacerbation of chronic progressive nephropathy and gastric irritation, including sporadic 
ulceration, at the lowest observable dose level in male rats, as well as signs of reversible 
cardiac inflammation and abdominal distension at a dose level of 200 mg/kg  in monkeys.  
Details of the adverse findings are provided in the Investigator’s Brochure.  
1.1.2  Summary of Clinical Data with Bexagliflozin  
Theracos has completed eight phase 1 studies to evaluate safety, tolerability, 
pharmacokinetics  (PK), pharmacodynamics (P D) and drug metabolism in healthy subjects, 
subjects with T2DM, and diabetic subjects with renal impairment.  Details of the 
pharmacology, efficacy, and safety assessments are described in the Investigator’s Brochure 
and summarized in the following sections . 
Bexagliflozin  exhibits high permeability and is a weak Pgp substrate and inhibitor.  It 
produces dose -proportional exposures in humans and animals.   Metabolism in humans is 
most similar to that in monkeys, and the principal pathway for biotransformation in humans 
is glucuronide formation.  The majority of bexagliflozin  and related metabolites are excreted 
within 48 to 72 h in humans, rats and monkeys, and there is no evidence of accumulation.  
Bexagliflozin  is neither a significant inducer nor inhibitor o f cytochrome P450 isozymes 
relevant for drug -drug interactions.  
In the course of bexagliflozin  therapeutic development, several formulations have been 
evaluated.  Immediate release c apsule formulations have been used in  the initial clinical 
pharmacology and phase 2 studies.  A program to develop a n extended  release tablet  
formulation that would reduce daily variation in the concentration of the compound was 
carried out and resulted in the identification of a mucoadhesive for mulation with the desired 
properties. The drug products exhibit a greater than 75% release of drug substance by 8 h  in 
simulated gastric fluid in vitro . 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 14 of 65 
 2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary objective of this study is to identify the optimal dose (s) through the comparison 
of mean HbA1c change in subjects who receive  bexagliflozin  tablets, 5 mg, 10 mg, 20 mg , or 
placebo, after 12 weeks of treatment.  
2.2 Secondary Objective s  
The secondary objectives of this study are the following:  
• To assess the change in HbA1c over time  
• To assess the efficacy of bexagliflozin tablets in lowering fasting plasma glucose ( FPG) 
over time  
• To assess the efficacy of bexagliflozin based on the proportion of subjects who reach the 
American Diabetes Association (ADA) and the Japa n Diabetes Society target  HbA1c of 
<7%  
• To assess the effect of bexagliflozin on systolic and diastolic blood pressure over time  
• To assess the effect of bexagliflozin on body weight over time  
• To assess the safety of bexagliflozin in subjects with T2DM  
 
Other exploratory objective  includes:  
• Population pharmacokinetic evaluation of bexagliflozin plasma concentration  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 15 of 65 
 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
THR -1442 -C-449 is a phase 2b multicenter, double -blind, placebo -controlled, dose range 
finding  study to assess the efficacy and safety of once daily bexagliflozin  in either treatment -
naïve type 2 diabetic subjects or subjects previously treated with one oral hypoglycemic  
agent  (OHA) .  The primary efficacy endpoint will be placebo -adjusted re duction in HbA1c , 
measured after 12 weeks of treatment .  Treatment naïve subjects are those who have never 
received prescription anti -diabetic medications or who have received no more than 14 days 
of prescription medications for diabetes in the 12 weeks pr ior to enrollment.  The study will 
enroll men and women  with T2DM and with HbA1c between 7% and 8 .5% (inclusive) at the 
screening visit (for subjects who are treatment naïve ) or with T2DM and with HbA1c 
between 6.5% and 8 .5% (inclusive) at screening visit (for subjects who have received one 
OHA  and who are willing and able to undergo a washout period. )   
Approximately 4 00 subjects who meet all the inclusion criteria, none of the exclusion 
criteria, and who consent to participate in the study are eligible to  be enrolled to complete  a 6 
to 10 week washout if needed and a 2 week placebo run -in period prior to being randomized.  
Subjects who can adhere to the  run-in medication dosing schedule (i.e., miss no more than 
one dosage  in 2 weeks ) and who have HbA1c between 7 and 8 .5% at baseline (visit S5) will 
be eligible for randomization and receive investigational product . A 20% screen fail  rate is 
expected by the end of run -in, leading to approximately 320 subjects eligible for 
randomization  to receive oral bexa gliflozin  tablets , 5, 10, 20 mg or placebo once daily for 12 
weeks in an outpatient setting.  Subjects who experience  hyperglycemia during the study may 
receive appr oved anti -diabetic medication.  Subjects will visit  their study site  at weeks 2, 6, 
and 12  for safety and efficacy evaluation , with a  follow up visit at week 14. 
Measurement  of bexagliflozin  plasma concentration over time  (sparsely sampled) will be 
conducted at 20 centers and  will include approximately 240 subjects  who consent to 
participa te the PK study . Three s amples from each subject will be drawn  at weeks 2, 6, or 12 . 
3.2 Research Methods and Procedures  
3.2.1  Washout and Run -in Period  
Eligible subjects who are not treatment naïve will discontinue their current OHA  and enter a 
6- or 10-week washout.  Tho se who are taking any  OHA except a thiazolidinedione will 
discontinue the medication for 6 weeks.  Subjects who are taking  a thiazolidinedione will 
discontinue the medication for 10 weeks.  At the start of the washout, each subject will be 
provided with di et and exercise counseling, a glucometer, a glycemic control diary in which 
to record daily fasting self -monitored blood glucose (SMBG) measurements and instructions 
regarding the appropriate circumstances  under which a  call to the clinic to register an 
observation of  hyperglycemia  should be made  (see Glycemic Control  below).  Two weeks 
after the start of the washout period each subject will participate in a phone interview with 
study staff for SMBG data review and general safety evaluation.  Subjects who re main 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 16 of 65 
 eligible at the end of the 6 or 10 week washout period will proceed to a 2 -week placebo run -
in period . Subjects will be ineligible if they exhibit  fasting blood glucose values ≥ 250 mg/dL 
on two consecutive days during the wash -out period.  
Eligible subjects who  are treatment naïve will not require a washout period and will proceed 
to the run -in period.  These subjects will be provided with diet and exercise counseling , a 
glucometer, and a glycemic control diary in which to record daily fasting SMBG 
measurements at the start of the 2 -week placebo run -in period.  
Treatment naïve subjects and subjects on background OHA  who complete the washout  will 
enter a 2 -week single -blind placebo run-in period.  Each subject will be provided with 
placebo run-in drug, do sing instructions, and instructions regarding the appropriate 
circumstances  under which a  call to the clinic to register an observation of  hyperglycemia  
should be made  (see Glycemic Control  below).  During the run -in, a placebo tablet should  be 
taken daily in the morning prior to eating or drinking; the medication should  be taken with 
water.  
Subjects will not be eligible for randomization if during the run -in period they: 1) have 
fasting blood glucose values ≥  250 mg /dL on two or more consecutive days, 2) omit more 
than one  of the  daily doses of placebo, 3) are deemed inappropriate for the study b y the 
investigator, or 4) on day -3 to day -5 prior to randomization, have HbA1c value < 7.0% or > 
8.5%.  The glycemic control requirement based on HbA1c values is outlined in Figure 1.  
 
Figure  1. Glycemic Control Requirement s Prior to Randomization  
 
Approximately 320 eligible subjects will be randomized in equal  ratio. Randomizatio n will 
be stratified by the background anti -diabetes treatment status ( treatment naïve or taking one 
OHA ).  
An assessment of bexagliflozin  pharmacokinetics will also be conducted at 20 centers  to 
include approximately 240 subjects. Samples will be taken during weeks 2, 6, or 12 . 

Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 17 of 65 
 3.2.2  Treatment Period  
The 12- week treatment per iod will start at randomization .  At the start of the treatment  
period each subject will be provided with the investigational product s, dosing instruction s, 
and a glycemic control diary in which to record SMBG  measurements .  Information related 
to the occurrence of hyperglycemic or hypoglycemic events will be recorded.  The 
investigational products  will be orally administered in the morning prior to eating or 
drinking; the medication should  be taken with water.  Rescue medication for hyperglycemia 
will be  allowe d when deemed medically necessary by the investigator . 
Each subject will be instructed to return to the clinic at weeks 2, 6, and 1 2 for safety and 
efficacy evaluations including revie w of adverse events and concomitant medication s, vital 
signs, ECG, physical examination, and blood and urine specimen collection s.  On the day of 
the clinic visit a minimum fasting period  of 10 hours  (h) must be confirmed prior to blood 
draw.  
Subjects will return to the clinic for a follow -up exit visit at week 14 or 2 weeks after the last 
dose of investigational product . Following the exit visit, subjects will be advised to see their 
primary physician to undergo  treatment to control their diab etes.  The duration of 
participation for each subject  is up to 29  weeks based on the treatment status of each 
potential subject.  
3.2.3  Glycemic Control Monitoring  
WASHOUT AND PLACEBO RUN-IN PERIODS  
During the washout and placebo run -in period subjects will be in structed to determine SMBG 
daily after fasting overnight for a minimum  of 10  h.  If the fasting blood glucose is ≥ 250 
mg/dL (13.9 mmol/L) the subject should contact the clinic within 24 h and the investigator 
will determine whether the participant should attempt to improve diet and exercise to 
maintain glycemic control or if the participant must withdraw  from the study and initiate a 
more intense pharmacological regimen for glucose control.  The participant will be excluded 
from further participation if fasting blood glucose  values are ≥250 mg/dL prior to 
randomization  on 2 or more consecutive days . Subjects with SMBG clinical signs or 
symptoms of hyperglycemia during the washout or run -in periods, including weight loss, 
blurred vision, increased thirst, in creased urination, or fatigue should be  excluded . 
TREATMENT PERIOD  
During the treatment period subjects will be advised to continue daily fasting SMBG 
measurements.  Subjects should contact the clinic if any fasting SMBG is ≥  270 mg/dL (15 
mmol/L) from wee k 1 to week 6 or  ≥ 240 mg/dL  (13.3 mmol/L) from  week 6 to week 12.  
Fasting b lood glucose values collected via SMBG will be evaluated at study visits by the 
investigator. In addition, hyperglycemia will be monitored by FPG measurement at each 
study visit.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 18 of 65 
 If hyperglycemia is identified through SMBG or FPG measurements, the investigator will 
determine whether the subject had fasted for a minimum of 10 h prior to the morning blood 
draw to ensure that the FPG value is truly a fasting sample.  If proper fasting  had not 
occurred, the subject will be asked to return for a repeat blood test within a week.  
During the 12 weeks of the treatment period, hyperglycemia should be managed first with 
diet and exercise counseling and should be managed with changes in the me dical therapy 
only if the investigator feels it is necessary for the well -being of the subject (see below, 
Prescription of Rescue Medication).  
If a concomitant medication for hyperglycemia is to be prescribed, a sample must be drawn 
prior to the administra tion of the rescue medication so that a final HbA1c value  can be 
ascribed to the latest date upon which  the sub ject was taking investigational product  as the 
sole therapy . 
PRESCRIPTION OF RESCUE MEDICATION  
Rescue medication for hyperglycemia should be pres cribed by the investigator at any time it 
is deemed necessary for the well -being of the subject.  During the 12 week  treatment  period , 
a review of diet and exercise counseling is suggested prior to prescription of rescue 
medication in the absence of specif ic medical indications for rescue medication.  Rescue 
medication is suggested if, after a review of diet and exercise counselling:  
1. more than 3 consecutive, daily, fasting SMBG measures are ≥ 270 mg/dL (15 mmol/L) 
from week 1 to week 6, or ≥ 240 mg/dL ( 13.3 mmol/L) from week 6 to week 12  
2. fasting SMBG values are ≥ 250 mg/dL (13.9 mmol/L)  and associated with clinical signs 
or symptoms of hyperglycemia (e.g . weight loss, blurred vision, increased thirst, or 
increased urination, or fatigue), and the signs  or symptoms are severe  
 
The investigator may provide rescue treatment with any approved medication for diabetes 
that is not otherwise contraindicated, with the exception of an SGLT2 inhibitor, as study 
subjects may already be taking a drug in that class a s a consequence of being randomized to 
receive bexagliflozin .  
Subjects who receive rescue medication due to poor glycemic control will continue to receive 
investigational product  and standard of care per investigator decision, according to current 
treatme nt guidelines.  Following the exit visit subjects will be advised to see their primary 
physician to undergo  treatment to control their diabetes.  
If hypoglycemia occurs in any subject prescribed rescue medication for hyperglycemia 
during the study, the total  daily dose of the rescue medication should be reduced 50% or 
more at the discretion of the investigator.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 19 of 65 
 OTHER  SAFETY  MONITORING  ACTIVITIES  
The safety monitoring activities will include assessment of vital signs, physical 
examinations, urinalysis, blood chemistry, hematology, adverse events, and concomitant 
medication use.  The occurrence of blood, liver, or skin disorders will be monitored through 
laboratory testing and evaluation of adverse event doc umentation.   
Adverse events of special interest as defined in the statistical analysis plan will include any 
clinical signs and symptoms that indicate adverse experience in the categories listed below .  
All such events must be appropriately documented wit hin source documentation.  
• Genital mycotic infections  
• Urinary tract infections  including urosepsis and pyelonephritis  
• Diuretic effects including hypovolemia  
• Hypotension episodes  
• Hepatotoxicity  
• MACE  
• Hypoglycemia  
• Falls and  fracture s 
• Malignancies  
• Hypersensitiv ity reactions  
• Acid -base disorders  
• Renal failure events  
 
DATA  AND  SAFETY  MONITORING  BOARD  
An independent Data and Safety Monitoring Board (DSMB) will monitor overall safety 
information during the bexagliflozin  development program.  The safety review activit y and 
potential risk benefit assessments utilized by the DSMB are defined in its charter.  
MAJOR  ADVERSE  CARDIOVASCULAR  EVENT  ADJUDICATION  
An independent cardiovascular adjudication committee has been  established to review , under 
blind , all potential cardio vascular events occurring during the study.  The events of interest 
include cardiovascular mortality, myocardial infarction  (MI) , stroke, hospitalization for acute 
coronary syndromes, urgent revascularization procedures, and other possible serious 
cardiova scular events.  The adjudicated events will be documented and archived to allow a 
meta -analysis to be performed at a later time.  No separate cardiovascular risk assessment 
will be performed based on events in the study population of the current protocol.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 20 of 65 
 3.3 Rationale for Study Design and Control Group  
THR -1442 -C-449 is designed to evaluate the efficacy and safety of bexagliflozin  tablets at 5 
mg, 10 mg,  and 20 mg strengths in the treatment of subjects with T2DM.  A randomized, 
double -blind study reduces bias and confounding by unmeasured factors and is the most 
suitable design to evaluate a new agent as a monotherapy in diabetic subjects.  Under the 
close monitoring detailed in this study, placebo is the appropriate control treatment in the 
subject population studied during the 12-week treatment  period.  In order to exclude the 
possibility that a subject’s HbA1c level at 12 weeks is determined by medications taken prior 
to the study, up to an 8 or 12 week combined washout and run -in period will be implemented 
prior to randomization.  All subjects will receive a placebo in the last 2 weeks prior to 
randomization to allow  compliance with the dosing regimen to be monitored.  Subjects with 
FPG levels  ≥ 250 mg/dL at rand omization will be excluded as a safety measure.  Diet and 
exercise counseling will be provided to all participating subjects to reduce risks of worsening 
diabetic conditions  or prolonged hyperglycemia.  
Results from published data in individuals with geneti c mutations in SLC5A2 , the gene 
encoding SGLT2, and in subjects that have been treated with other SGLT2 inhibitors, and 
from previous clinical studies in healthy or diabetic subjects treated with bexagliflozin , 
indicate that the risk of induced hypoglycemi a as a consequence of the loss of SGLT2 
activity should be minimal.  
Reduction in HbA1c directly reflects improvement in glycemic control and is a well 
validated surrogate for the risk of long-term microvascular complications of T2DM . HbA1c 
reflects mean gl ycemic control over 2 to 3 months, and therefore the primary endpoint of 
HbA1c measurement at 12 weeks will reflect the impact of bexagliflozin  compared to the 
placebo. Previous non -clinical and clinical study data have suggested  that the glucosuria and 
changes in HbA1c are likely to be less correlated when the baseline HbA1c is high but more 
correlated when the HbA1c is modestly elevated. To better demonstrate the dose relatedness 
of the treatment effect, a baseline HbA1c value of 7% to 8 .5% is included in  this pr otocol to 
allow clinical dose selection. N ear maximal glucosuria should be safe for the treatment of 
minimal diabetes  since hypoglycemia has never occurred  in trials with healthy subjects .  
A previously completed clinical study in Japanese subjects  demonstrated that a single  dose of 
bexagliflozin  of 3, 10, 30, or 90 mg strength resulted in a dose-dependent  glucosuria from  3 
mg to 30 mg with no incremental effect from  30 mg to 90 mg ( Figure 2 ).  This protocol is 
designed to assess the effect of bexagliflozin on  HbA1c at 12 weeks.  Strengths of  5, 10, and 
20 mg will be tested.   
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 21 of 65 
  
Figure  2. Dose related glucosuria in healthy Japanese subjects  
 
3.4 Study Duration and Dates  
Diabetic subjects will be screened within 3 weeks of enrollment.  Eligible subjects who 
provide  written consent will start a 2 to 12 week washout and run -in period prior to 
randomization to receive investigational product . Subjects will receive 12 weeks of treatment 
and be followed for 2 weeks after the last dose. The study duration from screening to follow -
up will be 16 weeks and up to 29  weeks overall  (Figure 3) . For details of the schedule and 
nature of the investigations, see the Schedule of Events in  Appendix 1 . 
 
Figure  3. THR-1442 -C-449 Study Design  
 020406080100
3 10 30 90UGE g/24 h  
Dose in mg  UGE, Japanese Healthy Subjects  

Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 22 of 65 
 4 STUDY POPULATION SEL ECTION  
4.1 Study Population  
The study population will include approximately 320 subjects diagnosed with T2 DM who are 
inadequately controlled by diet and exercise or by treatment with a single oral anti -diabet ic 
agent and who have an HbA1c level between 7% and 8 .5% at the time of randomization. 
Clinical sites in the US  and in  Japan are anticipated to recruit su bjects.   Clinical sites in other 
countries may also participate in the trial.  
4.2 Inclusion Criteria  
Prospective subjects must be:  
1. Men or women ≥ 20 years of age at screening. Women of childbearing potential must test 
negative by urine pregnancy test and agree to abstain from coitus  or use contraception 
during the entire study period to avoid any possible pregnancy.  Females who are 
surgically sterile ( by reason of hysterectomy  or oophorectomy) or postmenopausal ( most 
recent mense s more  than 12 months  prior to screening ) are eligible if they test negative 
by urine pregnancy test.  
2. Treatment naïve ( i.e., have never received prescription anti-diabetic medications or have 
received no more than 14 days of prescription  medications fo r diabetes in the 12 weeks 
prior to enrollment ) or currently taking  one OHA in combination with diet and exercise  
3. Diagnosed with T2DM with HbA1c levels at screening between 7.0% and 8.5% 
(inclusive) if treatment naïve  or with HbA1c levels between 6.5 an d 8.5% (inclusive) if 
on one oral anti -diabetic medication  
4. Currently having a body mass index (BMI) ≤ 40 kg/m2 
5. Taking stable doses of medication for hypertension or hyperlipidemia as determined by 
adherence to a regimen that has not changed for at le ast 30 days prior to screening  (if 
applicable ) 
6. Able to comprehend the study participation requirements and willing to provide written 
informed consent in accordance with institutional and regulatory guidelines  
7. Able to maintain adequate glycemic contr ol at the run -in visit ( for subjects who complete 
the washout ) 
8. Having  an HbA1c between 7.0 and 8.5% (inclusive) prior to randomization ( day -3 to -5) 
9. Capable of adhering to the  investigational product administration requirements as 
evidenced by omission of  no more than one dose of run -in medication  
 
4.3 Exclusion Criteria  
Subjects  who exhibit  any of the following characteristics  will be excluded from the study:  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 23 of 65 
 1. A diagnosis of type 1 diabetes mellitus or maturity –onset diabetes of the young (MODY)  
2. Current use of parenteral  therapy for treatment of diabetes (insulin or glucagon -like 
peptide -1 (GLP -1) receptor agonist therapy)  
3. Pregnan cy or current breastfeeding status  
4. Hemoglobinopathy or carrier status for hemoglobin alleles that affect HbA1c 
measurem ent 
5. Genitourinary tract infection (e.g. urinary tract infection, vaginitis, balanitis) within 6 
weeks of screening or history of ≥3 genitourinary infections requiring treatment within 6 
months of screening  
6. Estimated glomerular filtration rate (eGFR), as ca lculated by the modification of diet in 
renal disease study equation (MDRD), < 60 mL/min/1.73 m2 at screening  (Appendix 2) 
7. Uncontrolled hypertension ( average of two sitting measurements of systolic b lood 
pressure >160  mmHg  or diastolic blood pressure >  95 mmHg ) at screening  
8. A positive result on hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or positive 
result from screen for drugs of abuse  
9. History of  human immunodeficiency virus (HIV) infection  
10. Life expectancy < 2 years  
11. History of New York Heart Association (NYHA) Class 4 heart failure within 3 months of 
screening  
12. History of MI, unstable angina , stroke, or hospitalization for heart failure within 3  months 
of screening  
13. History of t reatme nt with an investigational drug within 30 days or within 7 half lives of  
the investigational drug, whichever is longer  
14. Previous treatment with bexagliflozin  or EGT0001474  
15. Currently or within 6 months of taking any SGLT2 inhibitors  from screening  
16. Currently participating in another interventional trial  
17. Not able to comply with the study scheduled visits  
18. Affected by a ny condition, disease, disorder, or clinically relevant abnormality that, in the 
opinion of the investigator, would jeopardize the subject’s appro priate participation in 
this study or obscure the effects of treatment  
19. ALT or AST ≥ 2.5 x upper limit of normal  (ULN ) or total bilirubin ≥ 1.5 x ULN  with the 
exception of isolated Gilbert’s syndrome at screening  
20. Exhibiting  fasting  plasma  glucose ≥ 250 mg/ dL (13.9 mmol/L) on two or more 
consecutive days prior to randomization or  exhibiting severe clinical signs or symptoms 
of hyperglycemia during the washout  or run -in period s, including weight loss, blurred 
vision, increased thirst, or increased urination, or fatigue  
21. FPG ≥ 250 mg/dL  at randomization  
22. Prior renal transplantation or evidence of nephrotic syndrome, defined as a urine 
albumin -to-creatinine ratio ( UACR) > 2000 mg/g at screening  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 24 of 65 
 5 STUDY TREATMENT S 
5.1 Description of Treatment s 
5.1.1  Investigational Product  
Bexagliflozin tablets, 5 mg, 10 mg, 20 mg, and placebo, are blue caplet -shaped, film -coated 
tablets that are intended for use in inve stigational studies in humans. The tablets contain 
excipients designed to promote extended release through a gastroretentiv e mechanism. The 
drug products exhibit a greater than 75% release of drug substance by 8 h  in simulated gastric 
fluid in vitro . 
The following investigational drugs will be used for oral administration:  
• Bexagliflozin  tablets, 5 mg: tablets containing 5 mg of bexagliflozin  
• Bexagliflozin  tablets, 10 mg: tablets containing 10 mg of bexagliflozin  
• Bexagliflozin  tablets, 20 mg: tablets containing 20 mg of bexagliflozin  
• Bexagliflozin  tablets, placebo: tablets containing no  bexagliflozin  
 
5.2 Treatments Administered  
Bexagliflozin  tablets should be taken in the morning prior to eating or drinking . The 
medication should be taken with water.  
5.3 Selection and Timing of Dose for Each Patient  
Prior clinical experience has shown  bexagliflozin  tablets  in strengths up to 90 mg per tablet  
are safe and well tolerated.  The highest planned dosage  of 20 mg  per day  is not expected to 
produce serious drug -related adverse events.  Doses of 10 mg and 30 mg bexagliflozin  in the 
tablet formulation have pr oduced near saturation  of UGE and statistically significant FPG 
lowering activity in prior studies.  The dose strengths of 5, 10, and 20 mg have been  selected 
to evaluate safety and efficacy of bexagliflozin . 
Dosing with bexagliflozin  tablets, 5, 10, 20 mg or placebo, will be based on randomized 
assignment.  All study subjects will be instructed to self -administer one tablet with water  
every  morning prior to eating or drinking.  There will be no change  of dose during the 12 -
week treatmen t period.  
5.4 Method of Assigning Patient s to Treatment Groups  
Eligible subjects who complete the run -in period and meet all study inclusion/exclusion 
requirements will be randomized in a 1:1:1:1 ratio to receive investigational product  
according to a computer -generated randomization schedule.  Subjects will be assigned to 
treatment groups in sequential order as they qualify for the study, using a centrally located 
and managed IWRS. Randomization will be stratified according to background anti -diabetic 
treatmen t status (treatment naïve or taking one OHA).  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 25 of 65 
 The study will be conducted at multiple investigative sites and will likely involve variable 
numbers of subjects at each site.  Enrollment will be on a competitive basis but each site will 
be capped at 32 subje cts.  Activation of investigational sites will be centrally controlled by 
IWRS.  Subject randomization will be deactivated for all sites when the planned number of 
subjects is met.  However, if a potential subject is in the washout period and wish es to 
participate in  the study, the subject will be allowed to continue and, if eligible, to be 
randomized.  
5.5 Blinding  
This is a double -blind placebo -controlled study.  The sponsor, investigators, study 
coordinators, pharmacists, study subjects, and the cardiovascular adjudication committee 
members  will be blinded to the study medication .  Upon randomization, each subject will 
receive a subject randomization number and a drug kit assigned to the subject.  To maintain 
blinding of the individual treatment a ssignment, the result s of urinary glucose testing will not 
be made available to  any study personnel or subjects.  
If knowledge of the treatment  is needed to manage the subject’s condition, the investigator 
will contact the IWRS to obtain the treatment assi gnment.  If unblinding occurs for any 
reason, the time and reason for breaking the blind will be recorded on the case report form 
(CRF) and the sponsor must be notified within 24 h.  
A designated statistician who is not involved with the study operation wi ll hold the treatment 
code s.  The unblinded treatment information can be provided to the DSMB to facilitate the 
evaluation of any clinically important increase in the rate of a serious suspected adverse 
reaction or to the designated safety contact when the  treatment information is required to 
determine if an expedited safety report must be submitted to regulatory agencies.   
The treatment assignment will continue to be withheld from the cardiovascular adjudication 
committee members until all global investig ational studies are completed and a meta -analysis 
to assess cardiovascular risk is conducted.  
5.6 Concomitant Therapy  
Subjects will be allowed to take medications or medicinal supplements prescribed to manage 
non-diabetic medical conditions during the study.  Any concurrent medication or 
supplement al treatment of other, non -diabetes, medical conditions should be continued at a 
stable dose and frequency for the entire study duration unless there is a clinical reason to 
change the dose or frequency.  
During the r un-in period, blood pressure medications can be altered to optimize blood 
pressure control at the discretion of the investigator. Blood pressure medications should not 
be altered during the treatment period unless it is medically necessary to do so.  If it is 
medically necessary to alter blood pressure medications during the treatment period, new 
diuretic medications should not be initiated and the dose and frequency of existing diuretic 
medications should not be altered.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 26 of 65 
 Subjects with hyperglycemia  during the treatment period will review diet and exercise 
counseling and/or receive rescue medication at the discretion of the investigator during the 
study. Anti -diabetic therapies prescribed to subjects for the purpose of treating 
hyperglycemia will be consider ed rescue medications (see Prescri bing Rescue Medication, 
above).  A blood sample will be collected to measure  the last HbA1c value prior to 
administration of any rescue medications. The rescue medications must be recorded as 
concomitant medications in the CRF.  
Subjects may receive any medications for adverse events that are necessary in the 
investigators’ judgment s. Concomitant medications prescribed at the time of the run -in 
period and during the study are to be recorded on the CRF. The medication name, do se, 
frequency, route of administration, date(s) of administration and reason for administration 
must be recorded . This documentation should continue through the treatment period and the 
follow up period.  
Any medication prescribed to a subject after enroll ment and prior to randomization, 
including contraceptives, must be recorded in the CRF.  
5.7 Restrictions  
5.7.1  Prior Therapy  
All subjects will continue regimens for medical conditions other than diabetes during the 
study as indicated above. No subject shall have bee n treated with an investigational drug 
within 30 days of screening or within a period equal to less than 7 half -lives of the 
investigational drug , whichever is longer.  No subject shall have been treated with an SGLT2 
inhibitor within 6 months of screening.  Subjects taking insulin  or GLP -1 receptor agonists 
are not eligible for this study.  
5.7.2  Fluid and Food Intake  
During the study, subjects will be counseled to remain adequately hydrated at all times.  In 
addition, subjects will receive counseling regarding an appropriate diet to achieve glycemic 
control based on standards of medical care in diabetes.  The diet should be low in saturated 
fat, high in fiber, and low in simple carbohydrates and should contain appropriate caloric 
content  to maintain weight.  Subject s will fast for a minimum of 10 h prior to the scheduled 
blood sample draws.  During fasting, only water will be permitted.  
5.7.3  Patient  Activity Restrictions  
Throughout the study period, subjects are to be counseled and encouraged to engage in a 
level of physic al activity that is appropriate for their physical condition.  For those without 
specific restrictions or limitations, at least 150 min/week of moderate activity is advised by 
the American Diabetes Association (American Diabetes, 2014 ) and an amount of exercise to 
balance energy intake in f ood by the Japanese Diabetes Association (JapanDiabetesSociety, 
2012 ). 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 27 of 65 
 5.8 Treatment Compliance  
Subjects will be provided with dosing instructions  when  the investigational product  is 
dispensed.  Subjects will also be instructed to bring their medication with them at every visit.  
During the run -in period, subjects will be excluded from  randomization if more than one 
dose has been omitted . 
At each visit the study staff will review SMBG diary and medication use with the subject and 
record the drug consumption  in the CRF.  Reasons for non - adherence will also be recorded in 
the protocol deviation log if applicable.  
5.9 Packaging and Labeling  
The fi nished products are packaged in HDPE bottles with a child resistant cap. There are two 
types of investigational product s. 
5.9.1  Run-in Kit  
One run -in kit  contains a bottle  of 15 bexagliflozin  tablets, placebo.  
The label attached to each run -in kit will contain t he protocol number, product identification, 
lot number, subject number, storage condition, sponsor’s name and address, and the 
investigational drug caution statement.  
5.9.2  Investigational Product  Kit 
One investigational product kit contains a bottle of  90 bexagliflozin  tablets, 5 mg, 10 mg, 20 
mg, or placebo.  
The label  attached to each investigational product  kit will contain the following information: 
the kit number, protocol number, product identification, blinded batch number, subject 
number, storage con ditions, sponsor’s name and address, CRO or ICC R name and address, 
investigator’s name, and the investigational drug caution statement.  
5.10 Storage and Accountability  
Bexagliflozin  tablets will be stored at controlled room temperatures of 15°C to 30°C (59°F to 
86°F).  The rescue medications will be stored in conditions specified in the manufacturers’ 
prescribing  information.  The sponsor will notify the sites of the process for retur ning unused 
drug.  
5.11 Investigational Product Retention at Study Site  
The investigational products should be stored in a secure area with limited access  at 
controlled room temperature until ready for dispensing to study subjects . The drug storage 
facility must  comply with the medication storage instructions. The trial staff must record the 
amount of investigational product dispensed to each subject on the dosing record. To ensure 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 28 of 65 
 adequate recordkeeping, subjects must bring all investigational products to each v isit. The 
remaining tablets will be accounted for in the CRF and drug consumption  forms.  The 
procedures for obtaining drug resupply will be provided by the sponsor.  At the completion of 
the trial, all unused drug must be returned to a sponsor -designated de pot after drug 
accounting  is verified by the sponsor  or its designee.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 29 of 65 
 6 STUDY PROCEDURES  
6.1 Informed Consent  
All subjects will be informed of the nature and purpose of the study and their written 
informed consent will be obtained during the pre -study screening procedures. A copy of the 
informed consent forms , including subject information, will be provided to each subject.  The 
investigator must educate potential subjects about the scientific importance of their data and 
the vital role that their participation has for the outcome of the entire study.  
6.2 Medical History  
The following information will be collected at the screening visit:  
6.2.1  General Demographics and Characteristics  
1. Date of birth, age, sex, and race, and whethe r a female subject is of childbearing potential 
or not  
2. Significant medical and surgical history, including dates o f diagnoses and procedures and 
whether the condition is ongoing, if applicable . 
 
6.2.2  Diabetes History  
1. History of all medications used to treat dia betes (to be recorded in the concomitant 
medication form), including start date, duration of use, and stop date, if applicable.  
2. History of complications due to diabetes, including nephropathy, retinopathy, 
neuropathy, non -traumatic amputations, and diabeti c ketoacidosis, including date of 
diagnosis  
3. Frequency of hypoglycemic events (per week) that are symptomatic or require assistance . 
 
6.2.3  Cardiovascular Disease History  
History of cardiovascular disease including presence of angina, congestive heart failure 
(classification, if present), known atherosclerotic cardiovascular disease, prior MI, 
cerebrovascular ischemia (TIA or stroke/cerebrovascular accident) and prior cardiac or 
periphera l re-vascularization procedures .  
History should include date of diagnosis and current status of diagnosis (resolved or 
ongoing).  
6.2.4  Medication History  
1. Use of prescribed or non -prescribed medications, including name of medication, 
indications for usage, start and stop dates, dose, and frequency  
2. Use of supplements, including over the  counter drugs, vitamins, herbal medicine, and 
dietary supplements within the past 30 days prior to screening.  A medication history will 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 30 of 65 
 include the medication used, indication for usage, start and stop dates, dose, and 
frequency.  
 
6.3 Physical Examination  
A complete physical examination will be performed by the investigator at screening and at 
the last study visit.  A complete physical examination will include measurement of body 
weight and height (height will be measured only at screening), general assessme nt of all body 
systems including the skin, head, eyes (including fundoscopic exam), ears, nose, throat, neck, 
heart, lungs, abdomen, lymph nodes, and extremities (including Achilles tendon reflex and 
foot exam).  The fundoscopic examination should be charac terized as normal or abnormal 
with description of any detected abnormality.  The Achilles tendon reflex should be graded as 
normal or abnormal.   The foot exam should assess skin and toenail lesions and be 
documented as normal or abnormal with description of  any detected abnormality.  
An abbreviated physical examination will include general assessment of the skin, heart, lungs 
and abdomen.  Abbreviated physical examinations will be performed by the investigator at 
all other time points as defined in the Schedu le of Events, unless clinically indicated.  
The body weight must be determined at clinical visits specified in the Schedule of Events 
(Appendix 1) using a scale that is calibrated regularly.    
6.4 Vital Signs  
Vital signs will be measured as indicated in the Sch edule of Events ( Appendix 1 ) and will 
include supine, sitting and standing blood pressure (BP)  measurements , pulse, temperature 
and respiratory rate.   
6.4.1  Blood Pressure and Pulse Measurements  
Devices de signed to measure BP from the finger or wrist may not be used. The left arm and 
same cuff sizes should be used for each measurement at all visits.  If the left arm cannot be 
used for BP measurements, the reason should be documented, and the right arm shoul d be 
used for BP measurements at all study visits.   
At each visit, BP measurements will be obtained using a calibrated sphygmomanometer 
while the subject is in sitting, supine, and standing positions.  A single pulse measurement 
should be taken just prior  to the BP evaluation in the sitting, supine, and standing positions.  
All readings are to be entered into the source document and CRF for all subjects. The date 
and time of BP measurements should be captured in the source document and CRF.  BP will 
be assessed first in the sitting position. Sitting BP and pulse will be measured after the 
subject h as been sitting for at least 5 minutes with feet on the floor and arm supported at 
heart level.  
After sitting BP measurement has been completed, supine and standing BP will be measured 
to evaluated orthostatic vital signs. Supine and standing blood pressu re measures will not be 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 31 of 65 
 used to determine eligibility for the study. First, the subject will lie flat  for 5 minutes and 
have pulse and supine blood pressure measured using the same equipment and arm as 
described for sitting BP. Once the supine BP measureme nt is complete, the subject will 
stand. Standing BP and pulse will be measured after 2 minutes of standing. For standing BP 
measurements, the arm should be supported and extended such that the cuff is at heart level.  
6.4.2  Temperature and Respiratory Rate  
Oral,  axillary, or ear temperatures are acceptable but they must be taken from the same 
measurement site during the study.  The subject should be advised to rest after strenuous  
physical activity  prior to a temperature measurement. When taking the temperature o rally, 
the subject must not have eaten, drunk, or smoked anything in at least the previous 15 to 20 
minutes, as the temperature of the food, drink, or smoke can dramatically affect the reading.   
Respiratory rate should be measured after at least 5 minutes of rest.  
6.5 Electrocardiography  
A 12 -lead electrocardiogram (ECG) will be conducted as listed in the Schedule of Events in 
Appendix 1  and whenever clinically indicated.  This procedure should be performed  in the 
supine position afte r at least 10 minutes of rest. ECG parameters measured will be the RR 
interval, PR interval, QRS duration, and QT, P -wave axis, and QRS -axis. Each ECG should 
also be assessed by the investigator for signs of ischemia, clinically significant hypertrophy, 
and clinically significant T -wave abnormalities.  
It is the investigator’s responsibility to review the results of the ECG as they become 
available. For each abnormal ECG result, the investigator needs to ascertain if this is a 
clinically significant change from the screening ECG for that individual subject ( this 
determination, however, does not necessarily need to be made the first time an abnormal 
result is observed.  The investigator may repeat the ECG to verify the results of the original 
result).   If the ECG result is determined to be a clinically significant and abnormal change 
from baseline for that subject, this is considered an AE.  
6.6 Diet and Exercise Counseling  
Subjects will receive counseling regarding an appropria te diet and exercise to aid in glycemic 
control based on standards of medical care in diabetes throughout the study.  In addition, all 
subjects are encouraged to consume enou gh non -sweetened liquids to maintain adequate 
hydration.  
6.7 Clinical Laboratory Tests  
6.7.1  Laboratory Parameters  
Subjects will be in a seated or supine position during blood collection.  Each laboratory test 
is outlined in Table 1 and the schedule is provided in Appendix 1 .   
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 32 of 65 
 Table  1. List of Laboratory Tests  
Test Name   Blood or urine  
Vol. (mL)  Shipment  
Hematology1 2 (blood)  Ambient  
- Hematocrit (Hct)  
- Hemoglobin (Hgb)  
- Mean corpuscular hemoglobin 
(MCH)  
- Mean corpuscular hemoglobin 
concentration (MCHC)  - Mean corpuscular volume 
(MCV)  
- Platelet count  
- Red blood cell (RBC) count  
- White blood cell (WBC) 
count with differential    
Serum Chemistry and Electrolytes1, 2  10 (serum)   Ambient  
- Albumin  (ALB)  
- Alanine aminotransferase (ALT)  
- Aspartate aminotransferase (AST)  
- Blood urea nitrogen (BUN)  
- Glucose  
- Bicarbonate (HCO 3) 
- Creatinine Chloride (Cl)  
- Total protein  - Calcium (Ca)  
- Magnesium  
- Phosphorus  
- Potassium (K)  
- Sodium (Na)  
- Total bilirubin  
- Direct bilirubin  
- Uric acid    
Glycemic Control ,1   Ambient  
- Fasting plasma glucose (FPG)  
- Hemoglobin A1c (HbA1c)   2 (plasma)  
2 (blood)   
Serum Lipids 1, 3  6 (serum)  Ambient  
- Total cholesterol (TC)  
- High -density lipoprotein cholesterol 
(HDL -C) 
- Triglycerides (TG)  - Low-density lipoprotein 
cholesterol (LDL -C), 
calculated  
- LDL -C, direct5   
Urinalysis4  10 (urine)  Ambient  
- Appearance  
- Bilirubin  
- Color  
- Glucose  
- Ketones  
 - Nitrite  
- Occult blood  
- pH 
- Protein  
- Specific gravity  
- Urobilinogen  
- Leukocyte esterase    
Urine drug screen5  10 (urine)  Ambient  
- Amphetamines  
- Barbiturates  
- Cocaine Metabolites  - Opiates  
- Benzodiazepines  
- Cannabinoids    
Infectious Disease Testing6  6 (serum)    
- HBsAg  - HCV    
Urine pregnancy test ( WOCBP )7   2 (urine)  Local  
Population PK Sampling8  6 (plasma)  Frozen  
- Bexagliflozin  plasma level     
1. Blood for clinical chemistry and hematology will be drawn after at least 10 h of fasting prior to 
breakfast (i.e. only water is allowed, no caloric intake).   
2. Lactate dehydrogenase (LDH), gamma -glutamyl transferase ( γ-GTP), creatinine kinase (CK), 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 33 of 65 
 Test Name   Blood or urine  
Vol. (mL)  Shipment  
and alkaline phosphatase (ALP) are not required routinely but will be included when clinically 
indicated.  
3. LDL-C will be calculated by the Friedewald equation. If triglycerides are > 400 mg/d L, the 
calculated LDL -C value is in valid by this equation and will be set as missing. Direct LDL -C will 
be determined in subjects whose baseline triglycerides are > 300 mg/d L. All subsequent LDL -C 
of these subjects will be determined by the same direct LDL -C measurements only.  
4. Urinalysis wi ll be collected routinely at all clinic visits  except S3 and V1 from a clean catch 
sample. Glucose results in the urinalysis reports  must be suppressed so the dosing blind can be 
maintained.  Testing strips with only the leucocytes and nitrate will be provided for immediate 
assessment at the clinical sites.  
5. Urine drug screen will be performed on screening visit only. Drug abuse screening includes 
amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, and cannabinoids.   
6. Infectious di sease testing will b e conducted at screening only.  
7. Urine pregnancy test  (UPT)  will be performed for WOCBP at all clinic v isits, except Visit s S3 
and V1. For surgically sterile or post - menopausal women, it will only be done at Visit S1.  
8. Blood samples for t he population PK analysis will be drawn at or during the weeks of V2 , V3 or 
V4 from 240 randomly selected subjects in participating trial centers.  
 
 
 
6.7.2  Sample Collection, Storage, and Shipping  
6.7.2.1  Hematology, Blood Chemistry, Serum Lipids, and Glycemic Control 
Assessments  
Blood samples for hematology, chemistry, serum lipids and glycemic control assessments 
will be collected.  Timing of collection is described in Section 7  and the Schedule of Events 
(see Appendix 1  and Appendix 2 ). 
The study staff will contact each subject prior to a scheduled clinic visit to confirm the time 
of the visit and to remind the su bject of the proper fasting  procedure .  A subject must be 
queried to assess compliance with a minimum 10 h fast prior to blood draw to ensure the 
FPG and triglycerides values can be accurately determined.  If a subject has not fasted for at 
least 10 h, the  subject must return as soon as can be arranged (within 7 days) to provide a 
specimen after proper fasting.  If the 10  h fasting sample is not collected within 7 days of the 
initially scheduled visit, the FPG will be considered missing.  
6.7.3  Urinalysis  
Urine samples will be collected per the schedule outlined in  Section 7 .  
Investigator or staff should document if pre -menopausal female subjects are menstruating 
and note it in the source documents since hematuria is likely to be identified on dipstick 
urinalysis.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 34 of 65 
 Urinalysis strips that assess leukocyte  esterase and nitrite and that do not report the presence 
or absence of glucose will be provided for immediate assessment at the clinical sites. Urine 
samples will also be transported to the central laboratory . 
Urine culture and microscopy  will be conducted at the central lab if the subject has a positive 
result on the leukocyte esterase or nitrite dipstick  tests at the clinical site. Dipstick urinalysis 
will also be cond ucted  at the central laboratory for assessment of parameters not measured at 
the clinical site. Positive leukocyte esterase or nitrite  results  recorded from  the central 
laboratory dipstick measurement will not trigger urine culture and microscopy .  
6.7.4  Populat ion PK Sampling  
Blood samples for the population PK analysis will be drawn when the subjects  return to the 
clinic during weeks 2, 6, or 12 from 240 selected subjects in participating trial centers. One 
blood sample will be drawn at each of the 3 time point s from each subject for a total of 3 
postdose samples per subject. Approximately 120 subjects will be sampled at 0.25-1 h, 7-10 
h, and 20-24 h post dose. Another 120 subjects will be sampled at 1.5 -3 h, 3.5 -6.5 h and 7 -10 
h postdose. The sampling time should take into consideration the study subject availability 
and can be on any of the days during the week of the specified clinical visits.  The precise 
dosing time and sample draw time must be recorded.  
Two mL (2 mL) of w hole venous blood will be collec ted from a peripheral vein. Samples 
will be placed in tubes containing K 2EDTA , stored on ice , and  centrifuged under 
refrigeration for at l east ten minutes at 3,000 rpm. After centrifugation, plasma will be 
removed and stored frozen in 3 aliquot s of 200 L at or below -20° C.  Processed frozen 
plasma samples will be transferred on dry ice to the analytical laboratory and will be stored at 
or below -20o C until analysis.  
Plasma concentrations of bexagliflozin will be determined by a validated LC -MS/MS 
method . Approximately 540 measurements of bexagliflozin plasma concentrations will be 
collected from an estimated 180 subjects who will have received active drug in this study.  
6.8 Dispensing Investigational product  
Each study subject will receive 1 run -in kit  at visit S4  and 1 investigational product  kit at 
visits V1 (week 1) . 
6.9 Efficacy Assessments  
6.9.1  HbA1c Determination  
The HbA1c values will be determined in a central laboratory using a method that is certified 
by the National Glycohemoglobin  Standardization Program (NGSP) and standardized to the 
Diabetes Control and Complications Trial (DCCT) reference assay.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 35 of 65 
 6.9.2  Body Weight  
Total body weight will be determined in clinical visit s as described in Section 6.3.  
6.9.3  Blood Pressure  
Systolic and diastolic blood pressure will be determined as described in the vital signs section 
(Section 6.4).  
6.10 Adverse Events Assessments  
Adverse event (AE ): Any untoward medical occurrence experienced by  a subject 
administered a n investigational  product . An AE  does not necessarily have a causal 
relationship with treatment. An AE can therefore be any unfavorable and unintended accident, 
sign (including an abnormal laboratory finding), symptom, or disease occurring during the 
period of use of a n investigational p roduct  or the period of follow -up, whether or not related 
to the investigational product.  
Serious adverse event (SAE ): Any event that results in any of the following outcomes:  
1. Death  
2. A life-threatening event, i.e., the subject was, in the opinion of the inv estigator, at 
immediate risk of death from the event as it occurred (this does not include an event that, 
had it occurred in a more severe form, might have caused death)  
3. A persistent or significant disability/incapacity  
4. An event that requires hospitalizati on or prolongs hospitalization  
5. A congenital anomaly/birth defect  
6. Any o ther medically significant events that, based upon appropriate medical judgment, 
may harm the subject and may require medical or surgical intervention to prevent one of 
the outcomes list ed above, e.g. allergic bronchospasm requiring intensive treatment in an 
emergency room or home; blood dyscrasias or convulsions that do not result in 
hospitalization; or the development of drug dependency or drug abuse.  
 
Non-serious adverse events are all  events that do not meet the criteria for a serious adverse 
event.  
Immediately Reportable Adverse Event (IRAE):  Any serious adverse event or any 
adverse event that necessitates discontinuation of investigational product , including 
pregnancy.  
Clinical Laboratory Changes:  It is the investigator’s responsibility to review the results of 
all laboratory tests as they become available.  For each abnormal laboratory test result  the 
investigator needs to ascertain if this is a clinically significant change fro m baseline for that 
individual subject ( this determination, however, does not necessarily need to be made the 
first time an abnormal value is observed.  The investigator may repeat the laboratory test or 
request additional tests to verify the results of th e original laboratory tests).  If the laboratory 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 36 of 65 
 value is determined to be a clinically significant and abnormal change from baseline for that 
subject, this is considered an AE.  
Hypoglycemia is defined as any FPG or SMBG value ≤ 70 mg/d L and documented as 
described in Section 6. 10.9. 
Any increase in liver function tests (AST, ALT, or bilirubin) greater than 3 times the ULN 
for the laboratory utilized will be considered a  clinical  laboratory adverse event.  
Severity: Adverse events will be graded on a 3 -point scale and reported as indicated on the 
CRF.  The intensity of an adverse experience is defined as follows:  
1 = Mild: discomfort noticed, but no disruption to daily act ivity;  
2 = Moderate:  discomfort sufficient to reduce or affect normal daily activity;  
3 = Severe: inability to work or perform normal daily activity.  
Investigational Product  Causality: An assignment made by the investigator based on the 
circumstances of the event and its analysis.  Cases with causal relationship classified as 
possible , probable  or definite are defined  as related. Cases with causal relationship 
categorized as not likely or unrelated are defined  as not related.   Relationship of an adverse 
event to dosing will be assessed as follows:  
Definite:  The event responds to withdrawal of the investigational product  (dechallenge), and 
recurs with rechallenge by administration of the investigational product . 
Probable:  There is a reasonable causal relat ionship between the investigational product  and 
the AE.  The event responds to dechallenge. Rechallenge is not required.  
Possible:  There is a reasonable causal relationship between the investigational product  and 
the AE.  Dechallenge is lacking or unclear.  
Not Likely : There is a temporal relationship to investigational product  administration, but 
there is not a reasonable causal relationship between the investigational product  and the 
event.  
Unrelated:  There is not a temporal or causal relationship to inves tigational product  
administration.  
6.10.1  Eliciting and Reporting Adverse Events  
The investigator will periodically assess subjects for the occurrence of adverse events.  To 
avoid bias in collecting information about adverse events, the investigator should ask 
subjects the following question: "How have you felt since you were last checked?"  All 
adverse events (serious and non -serious) reported by the subject must be recorded on the 
source documents and CRFs provided by the sponsor.   
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 37 of 65 
 In addition, the sponsor ’s Medical Monitor or its designated personnel must be notified 
immediately by telephone , email,  or fax of any immediately reportable adverse events 
(IRAE)_ according to  the procedure outlined below.  Special attention should be paid to 
recording hospitalization and concomitant medications.  
6.10.2  Immediately Reportable Adverse Events  
The investigator must report any serious adverse event (SAE), by telephone, email, or fax, to 
Theracos or its representative immediately after the investigator becomes aware of the event.  
An SAE form should be completed and sent by email or fax or overnight courier to the 
sponsor within 24 h of knowledge of the event.  
Non-serious events that require discontinuation of investigational product  (including 
laboratory abnormalities) should be reported to Theracos within 3 working days.  The IRAE 
form should be completed and sent by email or fax or overnight courier to the sponsor.   
Subjects experiencing an SAE should be followed clinically until their health has returned to 
baseline status or no further improvement in condition can be expected with further care .  It 
is expected that the investigator will provide or arrange appropriate supportive care for the 
subject.  
6.10.3  Pregnancy  
Women of childbearin g potential (WOCBP) who are sexually active must use an effective 
method of birth control during the course of the study, in a manner such that risk of failure is 
minimized.   
Before enrolling WOCBP in this clinical trial, investigators must review guideli nes about 
study participation for WOCBP.  The topics should generally include:  
1. General information  
2. Informed consent form  
3. Pregnancy prevention information  
4. Drug interactions with hormonal contraceptives.  
5. Contraceptives in current use.  
6. Guidelines for the fo llow-up of a reported pregnancy.  
 
Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy.  The 
subject  must sign an informed consent form stating the above -mentioned risk factors and that 
the consequences were discussed with her.  
During the study, all WOCBP should be instructed to contact the investigator immediately if 
they suspect they might be pregnant (e.g. missed or late menstrual cycle).  
If a subject or investigator suspects that the subject may be pregnant prior to investigational 
product  administration, the investigational product  administration must be withheld until the 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 38 of 65 
 results of serum pregnancy tests are available.  If the pregnancy is confirmed, the subject 
must not receive the investigational product  and must not remain or be enrolled in the study.  
If pregnancy is suspected while the subject is receiving study treatment, the investigational 
product  must be withheld immediately until the result of the pregnancy is known.  If 
pregnancy is confirmed, the investigational product  will be permanently discontinued and the 
subject will be withdrawn from the trial.  [Exceptions to study discontinuation may be 
considered for life -threatening conditions only after consultations with a Theracos Medical 
Monitor or designated personnel.]  
The investigator must immediately notify the Medical Monitor of any female subject who 
becomes pregnant within 30 days afte r investigational product  exposure.  The investigator 
must record the event on the Pregnancy Surveillance form and forward it to Theracos clinical 
or designated personnel.  
Protocol required procedures for study discontinuation and follow -up must be perform ed on 
the subject unless contraindicated by pregnancy ( e.g., x-ray studies).   Other appropriate  
pregnancy follow -up procedures should be considered if indicated. In addition, the 
investigator must report to Theracos, on the appropriate Pregnancy Surveillan ce form(s), 
follow -up information regarding the course of the pregnancy, including perinatal and 
neonatal outcome.  Infants will be followed for a minimum of six months.  
6.10.4  Procedure for Breaking the Blind  
As indicated in Section 5.5  above, the sponsor, study coordinators, pharmacists, study 
subjects, and the cardiovascular adjudication committee members  will be blinded to the 
treatment assignment during the study period .  The investigator should also remain blinded to 
the subject treatment during the entire study unless  knowledge of the subject’s treatment is 
required for clinical care and safety.  The Emergency Code Break module in the IWRS is 
used for such situations.   The investigator must confirm the intention to un blind the subject’s 
treatment to obtain the dose information in IWRS .  Upon completion of the unblinding, the 
system will send an alert to designated study team members that an unblinding event has 
occurred.  Documentation of breaking the blind should be r ecorded in the subject’s medical 
record with the date and time the blind was broken, and the names of the personnel 
requesting and authorizing unblinding.   The treatment assignment will continue to be 
withheld from the cardiovascular adjudication committee  members until all phase 3 studies 
are completed.  
6.10.5  Follow -up of Adverse Events  
6.10.5.1  Follow -up of Non -serious Adverse Events  
Non-serious AEs that are identified on the last scheduled contact must be recorded on the AE 
CRF wi th the current status noted.  All non -serious AEs that are ongoing at the time will be 
recorded as ongoing on the CRF.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 39 of 65 
 6.10.5.2  Follow -up of Post -Study Serious Adverse Events  
SAEs  that are identified on the last scheduled contact must be recorded on the AE CRF page 
and reported to Theracos  according to  the reporting procedures outlined in  Section 6. 10.2.  
These may include unresolved previously reported SAEs , or new SAEs.  The investigator 
should follow these SAEs  until the  events are resolved, or the subject  is lost to follow -up.  
Resolution means the subject  has returned to the baseline state of health, or the investigator 
does not expect any further improvement or worsening of the subject’s condition.  The 
investigator sho uld continue to report any significant follow -up information to Theracos  until 
the event has been resolved.   
Any new SAEs  reported by the subject  to the investigator that occur after the last scheduled 
contact, and are determined by the investigator to be  reasonably associated with the use of 
the investigational product , should be reported to the Theracos or designated personnel .  This 
may include SAEs  that are captured on follow -up telephone contact or at any other time point 
after the defined study perio d (i.e., up to last scheduled contact).  The investigator should 
follow SAEs identified after the last scheduled contact until the events are resolved, or the 
subject is lost to follow -up.  The investigator should continue to report any significant 
follow -up information to the sponsor  until the event has been resolved.  This study requires 
that subjects  be actively monitored for SAEs at least 14  days after the last treatment . 
6.10.6  Urinary Tract Infections  (UTIs) 
Events potentially representing UTIs,  including  cystitis, urethritis, pyelonephritis, or 
urosepsis , should be carefully evaluated and documentation of signs, symptoms, culture 
results for infectious agent, and treatment should be undertaken  when appropriate .  
The investigator should query the subject a t every clinical visit for symptoms that may be 
related to a UTI and, if appropriate, document these events as symptomatic UTI in the CRF  
unless an alternative diagnosis is present . In addition, a clean catch urine sample will be 
obtained at all clinical v isits and a urinalysis will be performed on that sample at every 
clinical visit. A positive urinalysis will be defined as one with detectable leukocyte esterase 
and/or nitrites. If the subject reports symptoms consistent with a UTI or the urinalysis at the  
clinical site is positive, a urine culture will be performed at the central laboratory. A positive 
urine culture will be defined as one with ≥ 105 CFU of any species. The investigator may also 
perform a urine culture using local resources if necessary for  clinical care.  
6.10.7  Genital Mycotic Infections (GMI s) 
The investigator will query the subjects for signs or symptoms that may represent a  GMI  at 
all clinical visits . GMI s will be diagnosed based on symp toms and , if appropriate, physical 
exam and  laboratory fi ndings . Investigators must exclude the possibility of  sexually 
transmitted infection s before diagnosing GMI . Diagnosis of GMIs must be documented in 
the CRF.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 40 of 65 
 6.10.8  Hepatotoxicity  
If plasma AST and/or ALT  concentrations  > 3 x ULN are detected, the investigator wi ll 
record in the source documents the date corresponding to the date of the laboratory 
abnormality; the type, frequency, and dose of any concurrent medications or supplements 
taken by the subject within the 14 days of the detected abnormality; and any symp toms or 
change in physical exam that have occurred since the prior assessment.   The investigator 
should perform additional laboratory and imaging tests to attempt to establish the cause of 
the AST and ALT elevations, including ruling out any potential cont ribution from bone or 
muscle etiologies.  
Any clinically significant increase in hepatic enzymes and specifically any ALT or AST >3x 
ULN requires immediate repeat test within 48 to 72 h to confirm the hepatic enzyme 
elevation and should be repeated based on the clinical situation at least every 96 h (4 days) 
until ALT and AST return to < 2.5 x ULN.  Study medication should be stopped  and the 
event should be reported as a laboratory adverse event within the CRF if the enzyme 
elevation is confirmed or worsening.  
Hepatotoxicity will be diagnosed and entered as an AE should any of the following occur:  
• ALT or AST > 8 x ULN;  
• ALT or AST > 3 x ULN and total bilirubin > 2 x ULN or INR > 1.5  
• ALT or AST > 3 x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).  
 
In the event of hepatotoxicity, investigational prod uct should be permanently discontinued.  
The investigator is encouraged to consult with the Medical Monitor regarding diagnostic 
evaluation for the hepatic enzyme elevations.  Consultation with a hepatologist may also be 
appropriate in some circumstances.  
6.10.9  Hypoglycemia  
Events of hypoglycemia or potentially representing hypoglycemia should be carefully 
evaluated.  
All subjects will be provided with a glucometer and diary for recording blood glucose 
measurements and signs and symptoms of hypoglycemia.  During t he study the subject is 
expected to record daily SMBG readings and all signs and symptoms that may potentially 
reflect hypoglycemia.  In the event of such signs or symptoms, the subject is expected to 
check the b lood glucose if it is reasonably  safe to do s o, and consume carbohydrate s, if 
appropriate, to treat hypoglycemia.  
The subject will be expected to record in the glycemic control diary the following 
information for each hypoglycemic event:  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 41 of 65 
 1. Signs and symptoms attributed to hypoglycemia and the time and  date on which they 
occurred  
2. SMBG reading at the time of the signs and symptoms attributed to hypoglycemia  
3. Time elapsed from the most recent meal to the onset  of  signs and symptoms  
4. Duration, intensity, and type of any exercise within the 24 h prior to th e signs and 
symptoms  
5. Type of treatment used (e.g., juice, crackers) for the signs and symptoms and whether 
assistance was required from another person to administer the treatment  
6. SMBG reading 15 minutes after treatment with carbohydrate and the time at whi ch this 
was measured  
7. Whether or not the signs and symptoms attributed to hypoglycemia resolved after blood 
glucose returned to normal . 
 
Subjects are encouraged to call the study clinic should signs and symptoms potentially 
related to hypoglycemia occur.  
At each study visit, the investigator is expected to review the glucometer and glycemic 
control diary with particular attention to any SMBG value ≤ 70 mg/d L and any recorded 
signs or symptoms potentially related hypoglycemia.  In addition, the investigator sh ould 
query the subject with regard to the occurrence of signs and symptoms potentially related to 
hypoglycemia even if none are recorded in the diary.  
In the event of a blood glucose value ≤ 70 mg/d L or signs and symptoms potentially related 
to hypoglycem ia, the investigator should complete the supplemental CRF which will include 
data from the glycemic control diary and action items to reduce future hypoglycemia 
episodes.  
Hypoglycemia events will be recorded in the hypoglycemia log under 5 categories:  
1. Severe hypoglycemia: an event requiring assistance by another person to actively 
administer carbohydrate, glucagon, or other resuscitative actions.  These episodes may be 
associated with sufficient neuroglycopenia to induce seizure or coma.  Plasma glucose 
meas urements may not be available during such an event, but neurological recovery 
attributable to the restoration of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration.   All such 
events should be recorded as serious adverse events in the CRF.  
2. Documented symptomatic hypoglycemia: an event during which typical symptoms of 
hypoglycemia are accompanied by a measured plasma glucose concentration ≤ 70 mg/dL 
(3.9 mmol/L).  
3. Asymp tomatic hypoglycemia: an event not accompanied by typical symptoms of 
hypoglycemia but with a measured blood glucose concentration ≤ 70 mg/dL (3.9 
mmol/L).  
4. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia 
are not accompani ed by a blood glucose determination but that is presumably caused by a 
blood glucose concentration ≤ 70 mg/dL (3.9 mmol/L).  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 42 of 65 
 5. Relative hypoglycemia: An event during which the person with diabetes reports any of 
the typical symptoms of hypoglycemia, and interprets those as indicative of 
hypoglycemia, but with a measured plasma glucose concentration > 70 mg/dL (3.9 
mmol/L).  
 
While each event meeting the criteria above will be entered into the hypoglycemia log, only 
critical hypoglycemia, documented symptom atic hypoglycemia, asymptomatic 
hypoglycemia, and probable hypoglycemia will be entered as AEs.  
In the event of asymptomatic hypoglycemia, the investigator should review the signs and 
symptoms of hypoglycemia with the subject to elicit a complete descript ion and should 
review proper glucometer technique to ensure that the low glucose value is not due to 
improper use of the glucometer.  
The investigator should be alert to the likelihood of improper glucose measurement technique 
if a study subject reports  an SMBG value < 55 mg/d L that is not associated with any signs or 
symptoms of hypoglycemia and is not treated by some form of glucose administration.   
In the event of probable symptomatic hypoglycemia, the investigator should encourage the 
subject to obtain glucose values, when possible, in the context of signs and symptoms of 
hypoglycemia, even if the glucose value is measured after treatment for the symptoms  is 
administered.  
If hypoglycemia occurs in any subject prescribed rescue medication for hyperglycemi a 
during the study, the total daily dose of the rescue medication should be reduced 50% or 
more at the discretion of the investigator.  
6.11 Concomitant Medication Assessments  
A concomitant medication is any medication that the subject has been  taking prior to 
enrollment and that the subject is expected to continue to take  for some portion of the trial, as 
well as any medication other than the investigational product that the subject takes during the 
course of the trial.  
The medications or treatment for controll ing hyp oglycemia must be recorded as concomitant 
medications in the CRF.  Any medication given to treat hyperglycemia is considered a rescue 
therapy and should be recorded in the concomitant medication log.  
Changes from  baseline anti -hypertensive therapy a nd their rationale  must be recorded in the 
CRF.  
All prescription and over -the-counter medications, including vitamins and herbal 
supplements, that subjects receive during the trial must be documented on the CRF.  This 
documentation should continue until the subjects complete the study .  
Concomitant medi cations will be coded using the World Health Organization Drug 
Dictionary (WHO -DD).  A table of concomitant medications based on the anatomic 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 43 of 65 
 therapeutic chemical classification (ATC) and preferred name will be produced.  A listing of 
concomitant medicatio ns will include all medications taken by any subjects during the course 
of the study.  
6.12 Removal of Patient s from the Trial or  Discontinuation of  
Investigational Product  Administration  
The investigator must emphasize to potential subjects the importance of co ntinued 
participation for the full duration of the trial during the informed consent process. Potential 
subjects should be informed that the trial procedures will allow additional medications to 
control hyperglycemia or other adverse conditions. It is also  important to emphasize that 
missing data and missed visits could affect  the entire trial . If subjects are dissatisfied with the 
conduct of the trial but have not withdrawn, the investigator should make an effort to address 
their concerns and retain them i n the trial if possible. In doing so, investigators must be 
careful that the efforts do not cross over into coercion . Investigator should encourage a 
subject to remain in the study even if the investigational product administration is stopped so 
that safet y information can be collected.  
Participation in a clinical trial is voluntary.  A subject can withdraw from the study at any 
time.  The sponsor or investigator may terminate the study for medical or administrative 
reasons.  If a decision is made to withdr aw a subject from the study, no further 
investigational product should be administered.  Even if the subject discontinues study 
medication, every attempt should be made to complete all required study evaluations and 
procedures.  Reasons for all withdrawals  should be recorded on the CRF.  Examples of 
reasons for withdrawal include:   
1. A protocol violation has occurred , 
2. A serious or intolerable adverse event has occurred , 
3. A clinically significant change in a laboratory parameter has occurred ,  
4. The sponsor or i nvestigator terminates the study, or  
5. The patient requests to be withdrawn  from the study.  
 
Subjects who do not complete the study but  who have received investigational product 
should have a follow -up examination, including a physical examination, vital sig ns, ECG and 
clinical laboratory tests according to  Section 7 . 
Subjects who withdraw from the study will not be replaced.  
6.13 Appropriateness  of Measurements  
The percentage of HbA1c is a widely used measure of chronic glycemia, reflecting average 
blood glucose levels over a 2 - to 3-month period of time. It is an accepted surrogate marker 
for risk of microvascular complications and is widely used as a measuremen t for the 
adequacy of glycemic management. Other study procedures and measurements in this 
protocol are widely used and generally recognized as reliable, accurate, and relevant for 
subjects with T2DM.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 44 of 65 
 7 STUDY ACTIVITIES  
The study activities at each clinic vi sit listed below are presented in Appendix 1 .  The 
required laboratory tests scheduled at each visit are listed in Appendix 2 .  Detailed  study 
procedures are described in Section 6 . 
A visit window of ± 3 days is allowed for all visits except visit V1.  Visit V1 is to be 
scheduled 3 days after visit S5 is complete and can be extended to 5 days depending  on 
HbA1c value availability.  
7.1 Screening (Up to 15 w eeks prior to randomization , visit S1)  
The screening can be performed from 3 weeks to 3 days before the start of the washout 
period for subjects who are taking background OHA  or 3 weeks to 3 days before th e start of 
the run -in period for subjects who are treatment naïve.  At the screening visit the study 
investigator will : 
• Explain the content of informed consent to the subject and collect signed informed 
consent  
• Obtain medical history and demographic information  
• Perform a complete physical examination including height and weight  
• Measure v ital signs, including blood pressures, pulse, temperature, and respiratory rate  
• Perform a 12-lead ECG measurement  
• Draw blood if  a minimum 10 -h fast has been completed  by the subject as described in 
Section 6.7.2.1 . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2  
• Collect a c lean-catch, mid -stream urine sample  for drug abuse  screening, urinalysis , and 
for UPT  for all female s 
• Evaluate the subject ’s suitability for enrollment according to the i nclusion and exclusion 
criteria  based on the information collected.  
 
7.2 Washout and Run -in Periods (Up to 12 w eeks prior to 
randomization ) 
The washout and run -in period is required for all enrolled subjects who are taking  an OHA. 
Enrolled treatment naïve subjects will not require any washout and will enter the run -in 
period.  
7.2.1  Washout of OHA (Visits S2 and S3)  
Two visits will be conducted during the washout period.  Visit S2 is a clinic visit.  At Visit S3 
each subject will be evaluated by the investigator or study staff via a phone interview 2 
weeks after washout starts; there wi ll be no on -site evaluation at Visit S3.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 45 of 65 
 7.2.1.1  Visit S2 (subjects taking one OHA)   
At the S2 visit the study investigator will : 
• Evaluate inclusion/exclusion criteria for eligibility  
• Counsel subject on appropriate d iet and exercise  
• Dispense g lucometer and train subject in SMBG determination and recording  
• Discontinue the OHA for 10 weeks if a subject is taking a TZD; discontinue the OHA for 
6 weeks if a subject is taking a non -TZD OHA  
• Collect c lean-catch, mid -stream urine for urinalysis and UPT for women of child bearing 
potential.  
• Assess pre-treatment signs and symptoms and record pre -treatment concomitant 
medications . 
 
7.2.1.2  Visit S3 – Phone interview (subjects in washout)  
At the S3 visit the study investigator will : 
• Review daily SMBG and glycemic control record for ea ch day during the prior 2 weeks  
• Assess any signs and symptoms of severe hyperglycemia, including increased urination, 
increased thirst, weight loss, and changes in vision  
• Assess pre-treatment signs and symptoms and record pre -treatment concomitant 
medicati ons. 
 
7.2.2  Run-in Period:  
7.2.2.1  Visit S4 (Week -2) 
At the S4 visit the study investigator will : 
• Counsel subject on appropriate d iet and exercise (for subjects who are treatment naïve 
and do not require washout)  
• Dispense g lucometer and instruct subject in  SMBG determ ination and recording (for 
subjects who are treatment naïve and do not require washout)  
• Review g lycemic control diary and SMBG (for s ubjects who complete  6 or 10 weeks of 
washout)  
• Measure v ital signs, including blood pressures, pulse, temperature, and resp iratory rate  
• Collect c lean-catch, mid -stream urine sample  for urinalysis and UPT for women of child 
bearing potential.  
• Dispense run -in kit for run -in period  
• Assess pre -treatment signs and symptoms and record pre -treatment concomitant 
medications . 
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 46 of 65 
 7.2.2.2  Visit S5  (Days -3 to -5) 
At the S5 visit the study investigator will : 
• Confirm inclusion/exclusion criteria for eligibility and review run -in drug compliance  
• Perform an abbreviated physical examination including weight  
• Review g lycemic control diary and SMBG results  
• Measure v ital signs, including blood pressures, pulse, temperature, and respiratory rate  
• Perform a  12-lead ECG  measurement  
• Draw b lood from subject if  a fast of 10 h or greater has been completed  as described in 
Section 6.7.2.1 . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2  
• Collect c lean-catch, mid -stream urine sample for urinalysis and UPT  for women of child 
bearing potential.  
• Assess pre -treatment signs and symptoms and record pre -treatment concomitant 
medications . 
 
7.3 Treatment  Period (week 1 to week 12)  
At the end of the run -in period, subjects  who have successfully completed run -in period a nd 
continue to meet inclusion/exclusion criteria will be randomized and enter the treatment  
period.  
7.3.1  Visit V1 (Day 1 of week 1)  
Visit 1, day of randomization, must be conducted after the HbA1c value from the sample of 
S5 visit is available for eligibility c onfirmation.  
At the V1 visit the study investigator will : 
• Confirm HbA1c value of 7.0 to 8. 5% based on the S5 sample results  
• Review SMBG and glycemic control record  
• Dispense investigational product based on randomization  
• Assess adverse events and record co ncomitant medications  
 
7.3.2  Visit V2 ( week 2) 
At the V2 visit the study investigator will : 
• Review SMBG and glycemic control record  
• Measure v ital signs, including blood pressures, pulse, temperature, and respiratory rate  
• Draw b lood from subjects who have fasted  a minimum of  10 h as described in Section 
6.7.2.1 . The specific laboratory tests scheduled for this visit are listed in Appendix 2  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 47 of 65 
 • Collect blo od specimens for sparse PK sampling from selected subjects in participating 
centers  
• Collect c lean-catch, mid -stream urine sample  for urinalysis in all subjects and for UPT 
for women of child bearing potential  
• Assess adverse events and record concomitant medications  
 
7.3.3  Visit V3 (week 6) 
At the V3 visit the study investigator will : 
• Review SMBG and glycemic control record  
• Measure v ital signs, including blood pressures, pulse, temperature, and respiratory rate  
• Draw b lood from subjects who have fasted  a minimum of  10 h as described in Section 
6.7.2.1 . The specific laboratory tests scheduled for this visit are listed in Appendix 2  
• Collect bl ood specimens for sparse PK sampling from selected subjects in participating 
centers  
• Collect c lean-catch, mid -stream urine sample  for urinalysis in all subjects and for UPT  
for women of child bearing potential  
• Assess adverse events and record concomitant m edications . 
 
7.3.4  Visit V4 ( week 12)  
At the V4 visit the study investigator will : 
• Review SMBG and glycemic control record  
• Perform an abbreviated physical examination including weight  
• Measure v ital signs, including blood pressures, pulse, temperature, and respiratory rate  
• Perform a 12-lead ECG measurement  
• Draw b lood from subjects who have fasted a  minimum of 10  h as described in Section 
6.7.2.1 . The specific laboratory tests scheduled for this visit a re listed in Appendix 2  
• Collect blood specimens for sparse PK sampling from selected subjects in participating 
centers  
• Collect c lean-catch, mid -stream urine sample  for urinalysis in all subjects and for UPT  
for women of child bearing potential  
• Retrieve remaining  study medication  and record the number of remaining tablets  
• Assess adverse events and record concomitant medications . 
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 48 of 65 
 7.4 Exit Visit or Early Termination Visit  
7.4.1  Visit V5 (week 14 or two weeks after the last dose of investigational product  
if a subject early terminates)  
At the V5 visit the study investigator will : 
• Review SMBG and glycemic control record  
• Perform a complete  physical examination including weight  
• Measure v ital signs, including blood  pressures, pulse, temperature, and respiratory rate  
• Perform a 12-lead ECG  measurement  
• Draw b lood from subjects who have fasted a  minimum of 10  h as described in Section 
6.7.2.1 .  The specific laboratory tests scheduled for this visit are listed in Appendix 2   
• Collect c lean-catch, mid -stream urine sample  for urinalysis in all subjects and for UPT  
for women of child bearing pot ential  
• Assess adverse events and record concomitant medications: If subject s have  an ongoing 
serious adverse event, the subject should  be followed until the adverse event is resolved 
or returns to baseline.  All possible attempts should  be made to document  resolution of 
acute and chronic toxicities.  
 
7.5 Early Termination Procedures  
Subjects removed from the study due to drug related toxicity will be followed until resolution 
or stabilization of the adverse event.  The s ponsor must be notified in the event that  a subject 
withdraws or has been  withdrawn from the study.  
Subjects who withdraw consent and have received investigational product  will have a follow -
up examination, including a complete physical examination, vital signs, ECG, and clinical 
laboratory test s (hematology, serum chemistry, and glycemic control).  
8 QUALITY CONTROL AND ASSURANCE  
The clinical research facility will be monitored by the study monitor to ensure correct 
performance of the study procedures and to ensure that the study is conducted according to 
the protocol and relevant regulatory requirements. CRF entries will be verified with the 
source documentation.  
Quality control principles will be applied throughout the performance of this study by 
following the SOPs of the CRO and the sponsor .  Review procedures will be implemented at 
the CRO for all documents that are generated in relation to the study.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 49 of 65 
 9 PLANNED STATISTICAL  METHODS  
9.1 General Considerations  
All statistical analyses will be performed using Version 9.4 or later of Statistical Analy sis 
Software (SAS®). 
Data summaries will use descriptive statistics (number of subjects [n], mean, standard 
deviation [SD], Q1, median, Q3, minimum, and maximum) for continuous variables, and 
frequency and percentage for categorical and ordinal variables.  If there are missing values, 
the number missing will be presented, but without a percentage .   All data collected will be 
included in by -subject data listings.  
Unless otherwise specified, all tests will be two -tailed using a 0.05 level of significance.  All 
confidence intervals (CIs) will be two -sided 95% confidence intervals.     
9.1.1  Handling Dropouts, and Missing Data  
Discontinuation criteria are explained in  Section 6.1 2.  Subjects who discontinue will not be 
replaced.  To the extent possible, attempts will be made to minimize the amount of missing 
data through measures planned in the study conduct.  But if m issing data are present f or the 
primary efficacy endpoint , they will be handled using  a multiple imputation approach.   The 
imputation method is as follows:  
As the primary analysis, o nly available data will be analyzed and data obtained after res cue 
will be  excluded and considered as missing.    The following sensitivity analyses will be 
conducted:  
• Missing endpoint information (including data obtained after rescue) will be imputed  via 
multiple imputation linear  regression approach. A total of 10 imputed datasets will be 
generated, and the primary efficacy endpoint analysis described below will be carried out 
on each imputed dataset; the analyses results will be combined across the 10 datasets 
using the standard techniques for multiple  imputed data sets in order to yield overall 
treatment comparison result s on the imputed data . 
• Missing endpoint data will also be handled based on the last observation carried forward 
(LOCF) technique.  T he last non -missing observation for a subject  (i.e., excluding data 
obtained after res cue) will be carried forward  for analysis . 
• Data collected after the start of rescue medication will NOT be considered missing , and 
the primary efficacy endpoint analyses will be performed based on all observed data.  
 
For all other endpoints , the missing data will not be imputed and only the observed data will 
be used in the analyse s. 
The number, timing, pattern, reason for and possible implications of missing values in 
efficacy and safety assessments will be investigated.  The  dropout patterns  may be assessed 
by graphical methods . 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 50 of 65 
 9.1.2  Multiple Comparisons / Multiplicity  
The primary objective of this study is to identify the effect of  bexagliflozin  tablets in three 
strengths on the placebo -corrected change in HbA1c from baseline  after 12 weeks of 
treatment.  All secondary endpoints are considered exploratory and adjustment for multiple 
endpoints will not be performed . 
9.2 Determination of Sample  Size 
Approximately 320 subjects will be randomized and eq ually  allocated to receive 
bexag liflozin  tablets , 5 mg,  10 mg , 20 mg , or placebo .   
The s ample size calculation for this study is based on a two group t -test with a two -sided 
significance at the 5% level and the following assumptions:  
1) The placebo -corrected population mean change from ba seline to Week 12 in HbA1c 
in the highest dose group of 20 mg will be -0.5%.  
2) The pooled standard deviation for the change from baseline to Week 12 in HbA1c for 
the active and placebo groups will be 0.9%. 
 
Under the above assumptions, an estimated sample size of 70 evaluable subjects per 
treatment arm yields approximately 90% power to detect a treatment difference between 
bexagliflozin  and placebo . A sample size of 80 per arm has been  selecte d to account for  a 
potential  drop-out and to allow adequate safety evaluation.   The total sample size for this 
study will be 320 subjects.  
This study will be conducted at multiple investigative sites and will likely involve variable 
numbers of subjects at each site.  Enro llment will be on a competitive basis but will be 
capped at 32 subjects from  each site.  
9.3 Analysis Populations  
9.3.1  Full Analysis Set  
All subjects who are randomized, take at least one dose of double -blind study medication, 
and have at least one post -randomization HbA1c measurement will be included in the Full 
Analysis Set (FAS).  All analyses of the FAS will be based on each subject’s r andomized 
assigned treatment.  
9.3.2  Safety Analysis Set  
All subjects who are randomized and take at least one dose of double -blind study medication 
will be included in the Safety Analysis Set.  Safety analyses will be based on the medication 
that was actually di spensed to each subject.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 51 of 65 
 9.3.3  Per Protocol Analysis Set  
The Per Protocol (PP) Analysis Set will include all subjects in the FAS who meet the study 
eligibility requirements and have no major protocol deviations that affect the validity of the 
efficacy measurements.  Protocol deviations that may result in subject  exclusion from the PP 
Analysis Set will be detailed in the Statistical Analysis Plan.  
9.4 Demographics and Baseline Characteristics  
Demographic characteristics include age, gender, race, ethnicity, and study center .  Baseline 
characteristics include baseline HbA1c values, blood pressure, body weight, body mass index 
(BMI in kg/m2), fasting plasma glucose level, and prior anti -diabetic treatment status 
(whether treatment naïve or not) .  Summary statistics by treatment group will include counts 
and percentages f or discrete variables, and means, SD, Q1, medians, Q3, minimum and 
maximum for continuous variables.  
9.5 Analysis of Efficacy  
All efficacy analyses will be performed based on the FAS.  The primary endpoint analysis 
will also be conducted using the PP Analysis  Set.  
For the primary endpoint  of HbA1c  change from baseline over 12 weeks of treatment , the 
MMRM analysis of covariance model (ANCOVA) with baseline HbA1c as a covariate will 
be fitted to the available data, incorporating all visits at which HbA1c was me asured for each 
subject including  the scheduled visits at weeks 2, 6, and 12 as well as the unscheduled visits 
for measurement of HbA1c  (NationalResearchCouncil, 2010 ). Treatment, study center, and 
stratification factor for randomization ( treatment naïve versus  taking one OHA  at baseline)  
will be applied as fixed effects, as will study week and study week -by-treatment interaction. 
From this model, an estimate of the treatment differ ence at week 12 will be generated, as will 
an assessment of whether this estimate is significantly different when comparing placebo 
with each dose of  bexagliflozin  at a two -sided 0.05 level of significance. An unstructured 
within -patient covariance structu re will be assumed. HbA1c values obtained after the start of 
rescue medication will be excluded from this primary analysis.  
The MMRM model is one approach to obtain treatment effect estimates in the presence of 
missing data. As sensitivity analyses for mi ssing data, the following will be performed:  
3) Missing HbA1c data (for weeks 2, 6, or 12) will be imputed via multiple imputation 
(MI), following which the MMRM will be repeated on the complete datasets with 
results combined across complete datasets using st andard MI techniques; HbA1c 
values collected after the start of rescue medication will be considered missing.  
4) Missing HbA1c data will be imputed via LOCF, following which the MMRM will be 
repeated; HbA1c values collected after the start of rescue medicatio n will be 
considered missing.  
5) HbA1c values collected after the start of rescue medication will NOT be considered 
missing , and the MMRM analyses will be re -performed.  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 52 of 65 
 For the primary efficacy model, a test for a significant baseline -by-treatment  interactio n will 
be performed  in a separate model, using a 0.100 alpha level.  If the baseline -by-treatment 
interaction is significant, then the ANCOVA assumptions are violated and an analysis of 
variance (ANOVA) model will be used instead , omitting the baseline cov ariate .   
A treatment by study center interaction effect will be added to the MMRM ANCOVA (or 
ANOVA) model used for the analyses of the primary efficacy variable.  If a statistically 
significant treatment by study center interaction effect is noted using a  0.1 level of 
significance, then separate analyses will be performed for each study center.   
In addition to the week 12 comparisons, the change from baseline to week 2 and week 6  will 
also be analyzed from the same MMRM ANCOVA model using 95% CIs for the between -
group mean changes.   The secondary efficacy endpoint, changes in HbA1c over time will be 
assessed descriptively using graphical methods  
To examine the dose response, tests for linear and quadratic dose -response relationships 
between the doses (0 [p lacebo], 5, 10 and 20 mg bexagliflozin ) and the change from baseline 
in HbA1c at week 12 will be conducted using a general linear model and appropriate 
orthogonal polynomial contrasts.  
Fasting plasma glucose , systolic and diastolic blood pressure, and weight will be analyzed 
using the same MMRM ANCOVA  model used in the primary efficacy analysis.    
For each subject, the post -baseline HbA1c values on or before week 12 will be assigned to a 
category of <  7% or ≥  7%.  Incidences of reduction of HbA1c to <  7% will be analyzed using 
a logistic regression model with effects for treatment, study center and baseline 
HbA1c.   Odds ratio and the corresponding 95% CI will also be presented.  
9.6 Analysis of Safety  
All safety analyses will be conducted based on the Safety Analysis Set.  
Safety data will include AEs, physical exam results, vital signs, ECG results, and clinical lab 
measurements of  serum chemistry, hematology, serum lipids, glycemic control parameters 
and urine sp ecimens .  Observed data will be listed by subject and summarized using 
descriptive statistics by treatment group  based on the Safety Analysis Set . 
9.6.1  Adverse Events  
Adverse events will be mapped to preferred term and body system using the Medical 
Dictionary f or Regulatory Activities (MedDRA ). AEs that begin after the first administration 
of investigational products  or existing AEs that worsen after the first dose of  study 
medication are considered treatment emergent AEs (TEAEs).  TEAEs will be assigned to the  
run-in period or the double blind randomization period in the same manner.  The number and 
percentage of subjects reporting TEAEs will be summarized for each treatment group by 
MedDRA system organ class and preferred term, then by severity, and by relatio nship to 
study treatment.  Drug -related AEs will be considered those to be at least possibly related to 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 53 of 65 
 investigational product  based on the investigator ’s assessment.   The number and percentage 
of subjects reporting serious AEs, and the number and percent age of subjects reporting AEs 
leading to treatment discontinuation will also be summarized for each treatment group by 
MedDRA system organ class and preferred term  
Adverse event listings will be provided for the following subsets:  
1. All TEAEs  
2. All TEAEs at least possibly related to bexagliflozin  
3. Serious AEs (if any)  
4. AEs leading to treatment discontinuation (if any)  
 
9.6.2  Adverse Event s of Special Interest  
Adverse events of special interest include  the following categories:  
• Genital mycotic infections  
• Urinary tract infections  including urosepsis and pyelonephritis  
• Diuretic effects including hypovolemia  
• Hypotension episodes  
• Hepatotoxicity  
• MACE  
• Hypoglycemia  
• Falls and  fracture s 
• Malignancies  
• Hypersensitivity reactions  
• Acid -base disorders  
• Renal failure events  
 
AEs of special interest will be defined  programmatically based on MedDRA system organ 
class and preferred term which will be predefined by a blinded medical reviewer and will be 
specified in the Statistical Analysis Plan.  
Event terms, signs, and sy mptoms will be documented in the listings.  The number and 
percentage of subjects who have experienced TEAEs of special interest will be summarized 
for each treatment group by type of AE.  
9.6.3  Clinical and Laboratory Events and Analyses  
Clinical and laboratory parameters  will be  measured at baseline , during the treatment period  
and at follow -up.  These variables include vital signs (blood pressure, pulse, respiration rate, 
and temperature), clinical laboratory  outcomes  (see Section 6.7  for a complete list) and ECG  
data. They will be summarized as changes from baseline.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 54 of 65 
 Laboratory data will be classified as low, normal or high relative to th e parameter’s reference 
range.  Laboratory abnormalities for each treatment will also be summarized with shift tables.  
Abnormalities as well as percent changes from baseline in the clinical and laboratory 
assessment will be listed.  
9.6.4  Physical Examination  
Physical examination findings incl uding body weight will be  collected at baseline and during 
the treatment period, safety ext ension phase and at follow -up. Abnormal findings at each 
visit will be tabulated as incidences by body system.  
9.6.5  Concomitant Medications  
Concomitant medications will b e coded using the World Health Organization Drug 
Dictionary ( WHO -DD). A by -subject listing of concomitant medications will include all 
medications taken during the study regardless of the timing fo r the start of the medication. 
All medications started prio r to the administration of the investigational product  will be 
included in the data but will be identified  as prior in the listing. Only the concomitant 
medication use will be summarized.  
9.7 Interim Analysis  
There will be no interim analysis. The final analys is will be performed after all subjects have 
completed the follow up assessments and all subject data have been cleaned and locked  in the 
study database . 
An independent Data and Safety Monitoring Board (DSMB) will monitor the safety of the 
subjects in this study.  The objectives of the DSMB are to assess drug safety and to allow for 
protocol modification or early s topping due to safety concerns.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 55 of 65 
 10 ADMINISTRATIVE CONSI DERATIONS  
10.1 Investigators and Study Administrative Structure  
Information regarding key pers onnel involved in the conduct of the study, including names 
and contact details of participating investigators, monitors, clinical laboratories, and technical 
departments and/or institutions, as well as information on members of additional study 
committees , will be found in the study files of the investigational site . 
10.2 Institutional Review Board  or Independent Ethics Committee 
Approval  
The study protocol, informed consent document, relevant supporting information, and all 
types of subject recruitment or adve rtisement information must be submitted to the 
Institutional Review Board ( IRB) or Independent Ethics Committee (IEC) for review and 
must be approved by the sponsor and the IRB /IEC  before the study is initiated. Any 
amendments or addenda to the protocol mu st also be approved by the IRB /IEC  prior to 
implementing changes in the study.  The investigator is responsible for keeping the IRB /IEC  
informed  of the progress of the study and of any changes made to the protocol as deemed 
appropriate, but in any case at l east once a year. The investigator must also keep the IRB /IEC  
informed of any SAEs occurring to subjects under their supervision.  
10.3 Ethical Conduct of the Study  
The procedures set out in this protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that the sponsor and investigator follow  
Good Clinical Practice Guidelines and the guiding principles detailed in the Declaration of 
Helsinki.  The study will also be carried out in keeping with applicable local laws and  
regulations.  An inspection by the sponsor representatives and/or their designee and/or  other 
authorized regulatory authorities representatives may occur at any time. The investigator 
must agree to the inspection of study -related records by the regulatory authority/sponsor  
representatives, and must allow direct access to source documents to the regulatory 
authority/sponsor  representatives.  
The investigator is responsible for complying with the protocol and all appropriate 
regulations and guidelines governin g global clinical research. Additionally, he/she is 
responsible for ensuring that all participating staff members are adequately trained and 
competent to perform his/her assigned tasks.  
Modifications to the study protocol will not be implemented by either the sponsor or the 
investigator without agreement by both parties. However, the investigator may implement a 
deviation from or a change of the protocol to eliminate any immediate hazards to the trial 
subjects without prior IRB /IEC  or sponsor approval/favor able opinion. As soon as possible, 
the implemented deviation or change, the reasons for it, and if appropriate, the proposed 
protocol amendment should be submitted to the IRB/IEC  and sponsor.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 56 of 65 
 Any deviations from the protocol must be fully explained and documented by the 
investigator.  The circumstances, action taken, and impact of the deviation on the trial must be 
communicated by the principal investigator to t he designated medical monitor. Any 
subsequent actions will be assessed by the designated medica l monitor and documented.  
10.4 Subject Information and Consent  
Prior to the beginning of the study, the investigator must have received from the Ethics 
Committee (EC) or IRB the written approval  or favorable opinion of the informed -consent 
form and any other wr itten informati on to be provided to subjects. The written approval of 
the IRB /IEC  together with the approved subject information/ informed consent forms must 
be filed.  The informed consent form must contain all elements required by authorized 
regulatory a uthorities and the ICH Good Clinical Practices (GCP) Guidelines (E6) , in 
addition to, any other elements required by Japan regulations or institutional policy.  
Written informed consent must be obtained before any study -specific procedure takes place.  
Participation in the study and date of informed consent given by the subject should be 
documented approp riately in the subject’s files.  A copy of the signed informed consent form 
must be provided to the subjec t. If applicable, it will be provided in a certifie d translation in 
the language understood by the subject, if not English.  Signed consent forms must remain in 
each subject’s study file and must be available for verification by study monitors at any time.  
10.5 Subject Confidentiality  
The information obtained d uring the conduct of this clinical study is confidential, and 
disclosure to third parties other than th ose noted below is prohibited. Information obtained 
during the conduct of this study will be used by the sponsor in connection with the 
development of th e investigational product . The study investigator is obliged to provide the 
sponsor with complete test results and all  data developed in this study. Subject -specific 
information may be provided to other appropriate medical personnel only with the subject’s  
permission. To ensure compliance with current ICH guidelines, data generated by this study 
must be available for inspection upon request by representatives of national and local health 
authorities, the sponsor, and the IRB /IEC  for each study site.  Study i nformation from this 
protocol will be p osted on clinicaltrials.gov and any local regulatory registry websites, as 
required by regulation.  
Subject names and other identifiers, such as photographs, audio, or videotapes, may not be 
disclosed in any publicatio n without prior written authorization from the subject.  
10.6 Study Monitoring  
An authorized sponsor representative will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
national and local government regulations and guidelines.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 57 of 65 
 The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities , other authorized regulatory authorities,  and IRB/IEC to 
inspect faciliti es and records relevant to this study.  
10.7 Case Report Forms and Study Records  
For each subject consented, a case report form (CRF), in electronic format, will be supplied 
and maintained by the CRO staff and signed by the investigator or authorized designee to  
indicate that he/she has reviewed and agrees with the entered data. This also applies to those 
subjects who fail to complete the trial.  The reason for subject withdraw al must be recorded in 
the case report form.  
Entries made in the CRF must be verifiable against source documents.  Source documents are 
defined as all medical records, medical notes, laboratory results, ECG traces and any 
additional document other than the CRF that has original subject information contained 
within it.  
All CRFs and source documents should be completed following GCPs and the CRO’s 
standard operating procedures.  
10.8 Data and Safety Monitoring Board  
An independent Data and Safety Monitoring Board (DSMB) will monitor overall safety 
information during the bexagliflozin  development p rogram. The safety review activity and 
potential risk benefit assessments utilized by the DSMB will be defined in its charter.  
10.9 Protocol Violations/ Deviations  
It is important to conduct the study according to the protocol.  Protocol deviation  waivers  
will n ot be prospec tively granted by the sponsor. If minor protocol deviations occur, the 
investigator must decide the most appropriate way to proceed with study activities and 
should consult the study representative for assistance.  If major protocol deviations occur, the 
sponsor’s medical monitor must be notified immediately so that a decision about whether to 
keep the subject in the study can be made.  
Only if an emergency occurs that requires a departure from the protocol for an individual 
subject can there be a departure witho ut the sponsor’s pre -approval. The nature and reasons 
for the protocol deviation will be recorded in the subject’s CRF, and the principal 
investigator must notify the Sponsor.  
Protocol violations/deviations must be reported in the final st udy report.  
10.10  Access to Source Documentation  
Authorized sponsor representatives will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
local and national government regu lations and guidelines.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 58 of 65 
 The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and records relevant to this study.  
Each center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP, and legal aspects. This will include on -site checking of the CRFs for 
completeness and clarity, cross -checking with source documents, an d clarification of 
administrative matters.  
All CRF data will be ent ered into a clinical database. Following the correction of any errors, 
the clinical database will be locked.  
10.11  Retention of Data  
The study file and all source data should be retained until no tification is given by the sponsor 
for destruction.  
If the investigator withdraws from the trial and relinquishes his/her responsibility for the 
maintenance and retention of records, he/she must notify the sponsor in writing so that 
arrangements can be made to properly store the trial materials.  
10.12  Publication and Disclosure Policy  
All data and results and all intellectual -property rights in the data and results derived from 
the study will be the property of the sponsor, who may utilize the data in various ways, such 
as for submission to government regulatory authorities or disclosure to other investigators.  
No publication or disclosure of study results will be permitted except as specified in a 
separate, written agreement between Theracos, Inc. and the inve stigator.  If results of this 
study are reported in medical journals or at meetings, all subjects’ identities will remain 
confidential.  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 59 of 65 
 11 REFERENCE LIST  
American Diabetes, A. (2014). Standards of medical care in diabetes --2014. Diabetes C are 
37 Suppl 1 , S14 -80. 
JapanDiabetesSociety (2012). Treatment Guidance for Diabetes 2012 -2013.  
Look, A.R.G., Wing, R.R., Bolin, P., Brancati, F.L., Bray, G.A., Clark, J.M., Coday, M., 
Crow, R.S., Curtis, J.M., Egan, C.M. , et al.  (2013). Cardiovascular effects of intensive 
lifestyle intervention in type 2 diabetes. The New England journal of medicine  369, 145 -154. 
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, 
Y., Yokoyama, H., Hishida, A ., et al.  (2009). Revised equations for estimated GFR from 
serum creatinine in Japan. American journal of kidney diseases : the official journal of the 
National Kidney Foundation  53, 982 -992. 
NationalResearchCouncil (2010). The Prevention and Treatment of Missing Data in Clinical 
Trials. In 978 -0-309-15814 -5, N.R. Council, ed., pp. 162.  
Palaniappan, L.P., Wong, E.C., Shin, J.J., Fortmann, S.P., and Lauderdale, D.S. (2011). 
Asian Americans have greater prevalence of metabolic syndrome despite lower body mass  
index. International journal of obesity  35, 393 -400. 
Santer, R., Kinner, M., Lassen, C.L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., 
Daschner, M., Ehrich, J.H., Kemper, M. , et al.  (2003). Molecular analysis of the SGLT2 gene 
in patients with r enal glucosuria. J Am Soc Nephrol  14, 2873 -2882.  
Scheen, A.J., and Van Gaal, L.F. (2014). Combating the dual burden: therapeutic targeting of 
common pathways in obesity and type 2 diabetes. The lancet Diabetes & endocrinology  2, 
911-922. 
Schwartz, S., Fabr icatore, A.N., and Diamond, A. (2012). Weight reduction in diabetes. 
Advances in experimental medicine and biology  771, 438 -458. 
van den Heuvel, L.P., Assink, K., Willemsen, M., and Monnens, L. (2002). Autosomal 
recessive renal glucosuria attributable to a  mutation in the sodium glucose cotransporter 
(SGLT2). Hum Genet  111, 544 -547. 
 
 
  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 60 of 65 
 Appendix 1  Schedule of Events  
 Screen -
ing Wash out Run-in Treatment  Follo
w Up  
Visit number  S1 S2 S3 S4 S5 V1 V2 V3 V4 V5 
Time to Randomization (weeks)1 up to 15 
weeks -12 
or -8 -10 
or -6 -2 -0.5 0 2 6 12 14 
Informed Consent  X          Screening for I/E criteria  X X   X      Demographics and medical h istory  X          Diet & exercise counseling2 
 X  X       Physical exam3 X    X    X X 
Body weight  X X   X  X X X X 
Diary & glucometer record review4   X X X X X X X X 
Start washout   X         Dispense Run -in Medication     X       Randomization       X     Vital signs  X   X X  X X X X 
ECG  X    X    X X 
Dispense study medication5 
     X     
Blood draw for clinical lab test6 X    X  X X X X 
Population PK sampling        X X X  
Urine collection7 X X  X X  X X X X 
AE  X X X X X X X X X 
Con Med   X X X X X X X X X 
1 Screening period may last up to 3 weeks ; washout period will be 10 weeks for subjects on a TZD 
or 6 weeks for subjects on other OHA, which includes a clinic visit (S2) and a phone interview 
(S3); run -in period is to be 2 weeks (S4 to S5); the treatment period (V1 to V4) will be 12 weeks.  
A visit window of ± 3 days is allowed for all visits except visit V1.  Visit V1 is to be scheduled at 3 
days after visit S5 and can be extended to 5 days pending on HbA1c value availability.  
2 Counseling  will be performed at S2 for washout and at S4 for treatment naïve subjects.  
3 A complete physical examination will b e performed by the investigator at screening (S1) and at 
the termination visit ( V5).  Abbreviated physical examinations will be performed by the 
investigator at all other time points, unless clinically indicated.  General  assessment of the skin, 
heart, lun gs and abdomen will be performed.  
4 Glucometer and diary will be dispensed to each enrolled subject at visit S2 (for subjects 
undergoing washout) or S4 (for subjects not undergoing washout), and subjects will be trained in 
glucometer use and SMBG recording. The SMBG record will be reviewed by the investigator at 
all subsequent visits.  
5 At visit V1, an investigational product kit  will be dispensed; subjects should bring in their study 
medication to be checked  on visits V2, V3, and V4 . 
6 Blood sample collection and laboratory tests at designated visits are listed in  Appendix 2 .  A 
minimum fasting time of 10 h must be confirmed prior to blood draw.  
7 UPT is scheduled for all women at screening and for WOCBP the reafter.  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 61 of 65 
  
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 62 of 65 
 Appendix 2  Schedule of Laboratory Tests  
  Screen
ing Washout  Run-in Treatment Period  FU 
Visit Number  S1 S2 S3 S4 S5 V1 V2 V3 V4 V5 
Time to Randomization (weeks)  up to 3 
wks -12 or 
-8 -10 
or -6 -2 0.5 0 2 6 12 14 
Hematology1 X       X   X   X X 
Serum chemistry electrolytes1 X       X   X   X X 
Fasting Plasma Glucose1 X      X   X X X X 
HbA1c X      X   X X X X 
Lipids2 X       X       X X 
Infectious disease testing3 X                   
Urine drug screen4 X                   
Urinalysis5, 6 X X   X  X   X X  X X 
Urine pregnancy test  (UPT)7 X  X  X  X   X X X X 
PK sampling8       X X X  
Total blood drawn (mL)  without PK  28 0 0 0 22 0 16 4 22 22 
Total blood drawn (mL)  with PK  28 0 0 0 22 0 18 6 24 22 
1. Blood for clinical chemistry and hematology will be drawn after 10 h of fasting prior to 
breakfast (i.e. only water is allowed, no caloric intake).   
2. LDL-C will be calculated by the Friedewald equation. If triglycerides are > 400 mg/dL, the 
calculated LDL -C value is invalid by this equation and will be set as missing. Direct LDL -C will 
be determined in subjects whose baseline triglycerides are > 300 mg/dL.  All subsequent LDL -C 
of these subjects will be determined by the same direct LDL -C measurements only.  
3. Infectious disease testing will be conducted at screening only.  
4. Urine drug screen will be performed on screening visit only. Drug abuse screening includes 
amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, and cannabinoids.   
5. Urinalysis will be collected routinely at all clinic visits except S2 from a clean catch sample. 
Glucose in the urinalysis results must be suppressed from the laboratory report so the dosing 
blind can be maintained.  Testing strips with only the leucocytes  and nitrate will be provided for 
immediate assessment at the clinical sites.  
6. UACR will be determined at screening only .  
7. Urine pregnancy test (UPT) will be performed for WOCBP at all clinic visits, except Visits S2. 
For surgically sterile or post - menopau sal women, it will only be done at Visit S1.  
8. Blood samples for the population PK analysis will be drawn at or during the week of V2 , V3, or 
V4 from 240 randomly selected subjects in participating trial centers.  
 
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 63 of 65 
 Appendix 3  Estimating Glomerular Filtration Rate  
The equation for estimating  glomerular filtration rate ( GFR) from serum creatinine is  the 
isotope dilution mass spectrometry (IDMS) -traceable Modification  of Diet in Renal Disease 
(MDRD) Study equation. This eGFR  calculator applies  serum creatinine (Scr) repor ted in 
mg/dL.  
The eGFR  for non -Japanese  subjects  should be calculated based on following equation   
eGFR (mL/min/1.73 m2) = 175 x (Scr)-1.154 × (Age)-0.203 x (0.742 if female) x (1.212 if 
African American)  
The eGFR  for Japanese  subjects  should be calculated based on following equation  (Matsuo et 
al., 2009 ) : 
eGFR (mL/min/1.73 m2) = 194 × ( Scr)-1.094 × (Age)-0.287× (0.739 if female)  
 
Bexagliflozin tablets   Theracos, Inc. 
Clinical Trial Protocol : THR -1442 -C-449  16 February 2015  
   
 
Confidential  Page 65 of 65 
 Appendix 5  Investigator’s Signature  
Study  Title:  A Phase 2b, Multi -center, Double -blind, Placebo -controlled, Dose 
Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets 
on HbA1c in Subjects with Type 2 Diabetes Mellitus  
Study  Number:  THR -1442 -C-449 
Final  Date:  16 February 2015  
I have read the protocol described above . I agree to comply with all applicable regulations 
and to conduct the study as described in the protocol .  
 
 
Signed:    Date:    
Principal Investigator  
 
 
 
 